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Abstract / Resumen

Abstract / Presentación 
 
  I 
 
Telomeres are specialized nucleo-protein structures at the end of chromosomes that protect them 
from degradation, repair activities and from fusing to other chromosome ends. The protein component of the 
telomere is called the shelterin and its main role is to maintain telomere structure and integrity, preventing 
genomic instability. Telomeres are elongated by the telomerase, a specialized enzyme which expression is 
very restricted in the adulthood. As a result, telomere shortening occurs within each cell division through the 
life of an organism. Dysfunctional telomeres, either owing to critical shortening or disruption of the shelterin 
complex, activate a DNA damage response, which eventually results in cell growth arrest, senescence and/or 
apoptosis, leading to a reduction of the regenerative potential of the tissues. For those reasons, telomere 
dysfunction is considered a main driver of aging but also a tumor suppressor mechanism. Mice deficient for 
the telomerase component Terc and mice deficient for the shelterin component Trf1 represent good models to 
study telomere dysfunction. Indeed, those mice show a high burden of DNA damage and cell growth arrest, 
leading to premature aging for Terc-deficient mice and to perinatal death for Trf1-deficient mice. In both 
mouse models, the additional abrogation of p53 ameliorated the phenotypes associated to accelerated aging 
and the lethality, but triggered cancer development. In this thesis, we aimed to address two issues: firstly, to 
analyze the role of the DNA damage response component CHK2 in the signalling of dysfunctional telomeres in 
vivo; and secondly, to test TRF1-mediated telomere dysfunction as a possible strategy for cancer therapy. 
To address the role of CHK2 in the signalling of dysfunctional telomeres, we generated doubly-
deficient mice for Chk2 and either Terc (Chk2-/- Terc-/-) or Trf1 (Trf1∆/∆ K5Cre Chk2-/-). We show that Chk2 
deletion improves Terc-associated phenotypes, including lifespan and age-associated pathologies. Similarly, 
Chk2 deficiency partially abolishes perinatal mortality and attenuates degenerative pathologies of Trf1∆/∆ 
K5Cre mice. In both cases, we show that those effects are mediated by a significant attenuation of p53/p21 
signalling pathway. Our results demonstrate a role for CHK2 in the in vivo signalling of dysfunctional 
telomeres. 
To test TRF1 as a possible target for cancer therapy, we generated a conditional deletion of Trf1 in 
the lung cancer mouse model K-RasG12V, both in a p53-proficient and p53-deficient genetic background. Trf1 
abrogation fully impaired K-RasG12V-induced lung tumorigenesis in the presence of p53. In the absence of p53, 
Trf1 deletion delayed tumor onset and impaired progression to malignancy, increasing mouse survival. The 
anti-tumorigenic effect of Trf1 deletion was accompanied by induction of telomeric DNA damage, apoptosis, 
decreased proliferation, G2-arrest, and endoreduplication. These results were validated in xenograft and 
allograft models by downregulation of TRF1 in cell lines derived from already established p53-deficient K-
RasG12V mouse and human lung carcinomas. In addition, we generated a conditional whole-body Trf1 deletion 
in adult mice during more than 1.5 months and showed that this transient TRF1 deficiency did not impact on 
mouse survival and viability. Together, these results demonstrate that Trf1 deletion effectively impairs the 
growth and progression of lung cancer without severe effects in normal tissues. Induction of TRF1-mediated 
acute telomere dysfunction can be considered as a potential new therapeutic strategy for lung cancer. 
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II 
Los telómeros son estructuras nucleo-proteicas especializadas que se encuentran en el extremo de 
los cromosomas, y que los protegen de degradación, de actividades de reparación y de fusionarse con otros 
extremos cromosómicos. El componente proteico del telómero se llama shelterina y su papel principal es 
mantener la estructura e integridad del telómero, evitando la inestabilidad genética. Los telómeros son 
elongados por la telomerasa, una enzima especializada cuya expresión está muy restringida en la edad 
adulta. Como consecuencia de esto, en cada división celular se produce un acortamiento telomérico, a lo 
largo de la vida de un organismo. Los telómeros disfuncionales, bien debido a acortamiento telomérico por 
debajo de una longitud crítica, o bien debido a la disrupción del complejo shelterina, activan una respuesta 
frente al daño del ADN, que finalmente resulta en parada del ciclo celular, senescencia y/o apoptosis, 
llevando a una progresiva pérdida de la capacidad regenerativa de los tejidos. Por estas razones, la 
disfunción telomérica está considerada como unos de los principales agentes de envejecimiento, pero es 
también un mecanismo supresor de tumores. Ratones deficientes en el componente Terc de la telomerasa o 
en el componente Trf1 de la shelterina constituyen buenos modelos para estudiar la disfunción telomérica. En 
efecto, estos ratones presentan una alta carga de daño al DNA y una parada de ciclo celular, que conducen a 
un envejecimiento prematuro en los ratones deficientes en Terc y a una muerte perinatal en el caso de los 
ratones deficientes en Trf1. En ambos modelos de ratón, la deleción adicional de p53 alivia los fenotipos 
asociados al envejecimiento y la letalidad, pero promueve la tumorogénesis. Esta tesis tuvo por objeto 
abordar dos problemáticas: la primera fue analizar el papel de CHK2, un componente de la respuesta frente 
al daño en el ADN, en la señalización de telómeros disfuncionales; y la segunda, testar la disfunción 
telomérica mediada por TRF1 como una posible estrategia para la terapia anti-cáncer.  
Para elucidar el papel de CHK2 en la señalización de los telómeros disfuncionales,  generamos dos 
ratones doblemente deficientes en Chk2 y a la vez en Terc (los ratones Chk2-/- Terc-/-) o bien en Trf1 (los 
ratones Trf1∆/∆ K5Cre Chk2-/-). Hemos demostrado que la deleción de Chk2 mejora los fenotipos asociados a 
la deficiencia de Terc. De manera similar, la deleción de Chk2 abole parcialmente la mortalidad perinatal y 
atenúa las patologías degenerativas de los ratones deficientes en Trf1. En ambos casos, mostramos que 
estos efectos son mediados por una atenuación significativa de la señalización de las vías p21/p53. Nuestros 
resultados muestran que CHK2 juega un papel en la señalización in vivo de los telómeros disfuncionales.   
Para testar TRF1 como una posible diana para terapia anti-cáncer, generamos una deleción 
condicional de Trf1 en el modelo murino de cáncer de pulmón K-RasG12V, tanto en un fondo genético p53 
competente como en un fondo deficiente para p53. La deleción de Trf1 impide la tumorigenesis inducida por 
K-RasG12V en el fondo genético competente para p53. Además, en un fondo genético deficiente para p53, la 
deleción de Trf1 retrasa la aparición de tumores e impide la malignificación,  aumentando la supervivencia de 
los ratones. El efecto anti-tumorogénico de la deleción de Trf1 se acompaña de inducción de daño al ADN 
telomérico, apoptosis, reducción de la proliferación, parada del ciclo celular en G2 y endo-reduplicación. 
Estos resultados se validaron en modelos de alotransplante y xenotransplante, disminuyendo los niveles de 
TRF1 en líneas celulares derivadas de carcinomas ya establecidos K-RasG12V p53-/- humanos y de ratón. 
Adicionalmente, se delecionó Trf1 en todo el organismo adulto durante más de 1,5 meses y se demostró que 
esta deficiencia parcial y transitoria en Trf1 no afecta a la supervivencia ni a la viabilidad del ratón. En 
conjunto, estos resultados demuestran que la deleción de Trf1 obstaculiza eficazmente el crecimiento y la 
progresión del cáncer de pulmón sin efectos adversos graves en los tejidos normales. La inducción de una 
disfunción telomérica aguda mediada por TRF1 podría ser considerada como una nueva estrategia 
terapéutica potencial para el cáncer de pulmón.  
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1. Telomeres 
 
1.1. The telomere primary structure  
The ends of the linear chromosomes are protected of degradation and repair activities by a 
nucleo-protein structure, the telomere (Blasco, 2007a; de Lange, 2005; Palm & de Lange, 2008). 
Telomeres were firstly described in Drosophila and maize cells by Hermann Müller and Barbara 
McClintock, respectively (McClintock, 1941; Müller, 1938). They observed that intact chromosome ends 
presented a distinct behavior than broken chromosome fragments: intact telomeres were strangely 
resistant to the effects of the mutagenic X-rays and were somehow protected from chromosome fusions.  
 
1.1.1. The telomeric DNA 
The telomeric DNA is a highly conserved structure in eukaryotic chromosomes, does not 
contain genes and it is formed by a tandem repeated sequence rich in G/T nucleotides (Wellinger & 
Sen, 1997). In vertebrates the repeated sequence is TTAGGG (Meyne et al, 1989). The G-rich strand of 
the telomeric DNA ends in a short 3’ single-stranded overhang, that is essential for the telomere 
structure and function as we will explain later (Griffith et al, 1999; Klobutcher et al, 1981) (Figure 1).  
Telomeres present the chromatin modifications characteristic of constitutive heterochromatin, 
such as H3K9 and H4K20 histone trimethylation and HP1 binding (Blasco, 2007a; Garcia-Cao et al, 
2004). Indeed, telomeres possess the heterochromatin property of silencing nearby genes (Baur et al, 
2001; Koering et al, 2002). 
Telomere length varies across species and within species, it depends on the developmental 
stage and cell type (Flores et al, 2008; Marion et al, 2009). On average, human telomeres span 10-15 
kb, while mouse telomeres are 25-50 kb long (Blasco, 2005). These differences in telomere length do 
not compromise telomere function as long as the telomere remains above a certain critical length, below 
this critical length telomeres lose their protective role and genetic instability can occur (Blasco et al, 
1997; Lee et al, 1998).  
 
Figure 1. The telomeric DNA structure. Top: mouse metaphase 
chromosome treated with a fluorescent-labeled probe that hybridizes to 
telomere repeats. Middle and bottom: schematic depiction of telomeric DNA, 
composed of tandem-repeated G/T rich sequences, in vertebrates TTAGGG.  
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1.1.2. The telomeric protein complex: the shelterin  
Mammalian telomeres are bound by a specialized protein complex known as shelterin (de 
Lange, 2005; Palm & de Lange, 2008). Mammalian shelterin is composed of 6 core proteins: the 
telomere repeat factors 1 and 2 (TRF1 and TRF2), the TRF1-interacting factor 2 (TIN2), the POT1-TIN2 
organizing protein TPP1 (also known as TINT1, PTOP or PIP1) and the repressor/activator protein 1 or 
RAP1 (de Lange, 2005) (Figure 2).  
Shelterin constitutes the so-called “capping” of the telomeres, and is required for the protective 
role of telomeres, impeding the enzymatic degradation of the telomere and the fusion with other 
chromosomes (de Lange, 2005). Shelterin also prevents the telomeres from being recognized as 
double-strand breaks (DBSs) and thus from activating a DNA damage response (de Lange, 2005). Last, 
some shelterins are implicated in the regulation of telomere length, as we are going to detail in section 
2.3. An outline of shelterin functions is shown in Table 1. 
 
 
Figure 2. The mammalian shelterin. From de Lange et al., 2009.  
 
TRF1 and TRF2 
TRF1 and TRF2 present a high degree of homology (Bianchi et al, 1997; Broccoli et al, 1997). 
They form homodimers and directly bind to the double-stranded part of the telomere by their C-terminal 
Myb domain (Bianchi et al, 1997; Broccoli et al, 1997). Both TRF1 and TRF2 regulate telomere length 
(Smogorzewska et al, 2000). TRF2 and to a lesser extent TRF1 have an important role in telomere 
capping and in the inhibition of the DNA damage response (Martinez et al, 2009b). TRF1 has an 
exclusive and esential role in the replication of telomeric DNA (Martinez et al, 2009b; Sfeir et al, 2009). 
 
POT1 
POT1 specifically binds to the single-stranded end of the telomere, the 3’ overhang (de Lange, 
2005; Klobutcher et al, 1981). It is connected to the shelterin complex by direct binding to TPP1 and has 
an important role in the protection of the 3’ overhang, in the inhibition of the DNA damage response and 
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in the regulation telomere length (Denchi & de Lange, 2007; Loayza & De Lange, 2003; Ye et al, 2004b). 
In mice, there are two distinct forms of POT1: POT1a and POT1b (Hockemeyer et al, 2006).  
 
TIN2 
TIN2 serves as a bridge between the double-stranded and the single-stranded telomere binding 
proteins of the shelterin complex (Kim et al, 2004; Ye et al, 2004b). Indeed, TIN2 interacts both with 
TRF1 and TRF2, stabilizing TRF2 binding to the telomere (Houghtaling et al, 2004; Kim et al, 2004; Ye 
et al, 2004a). TIN2 interacts also with TPP1, mediating the recruitment of POT1 to the telomere (Ye et 
al, 2004b).  
 
RAP1 
RAP1 binds to telomeres through its interaction with TRF2 (Li & de Lange, 2003; Li et al, 2000). 
RAP1 represses homology-directed repair at telomeres and it is not required for correct telomere 
capping (Martinez et al, 2010; Sfeir et al, 2010). Instead, RAP1 has several extratelomeric roles such as 
modulating the transcription of metabolic genes and silencing of subtelomeric genes (Martinez et al, 
2013; Martinez et al, 2010; Teo et al, 2010). 
 
TPP1 
TPP1, also named ACD, is implicated in the regulation of telomere elongation (Tejera et al, 
2010; Xin et al, 2007), by recruiting the TERT subunit of the telomerase enzyme to telomeres (Tejera et 
al, 2010). It has been proposed that the anchoring of TPP1 to TIN2 is important for telomerase 
recruitment (Abreu et al, 2010). TPP1 recruits POT1 to the telomere (Chen et al, 2007; Kibe et al, 2010). 
 
 
SHELTERIN ROLE AT TELOMERES 
POT1 3’ overhang protection 
TRF1, TRF2, POT1, TIN2, TPP1 Telomere capping 
TRF1, TRF2, POT1, TIN2, TPP1, RAP1 Telomere length regulation 
TRF1, TRF2, POT1, RAP1 DNA damage response inhibition 
TRF1 Telomere replication 
 
Table 1. Role of the shelterin proteins. 
 
 
Finally, other proteins associate to the shelterin complex. Precisely, TRF2 interacts with 
components of DNA repair pathways like MRN complex (Zhu et al, 2000), DNA-PKcs (Hsu et al, 2000), 
PARP1 (Gomez et al, 2006), and the nucleases XPF and Apollo (Lenain et al, 2006; Zhu et al, 2003). 
TRF1 interacts with the negative regulator of telomere length PINX1 (Zhou & Lu, 2001), and with two 
enzymes that regulate TRF1 binding to the telomere: Tankirases 1 and 2 (Smith & de Lange, 2000; 
Smith et al, 1998). Ku 70/80 interacts with both TRF1 and TRF2 (Hsu et al, 2000; Song et al, 2000). 
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1.2. The telomere secondary structure: the T-loop and its end-protection role 
In vivo, the telomeric DNA adopts a higher order conformation that stabilizes the telomere 
structure, called the T-loop (Goytisolo & Blasco, 2002; Griffith et al, 1999). T-loop structure is formed 
when the telomeric 3’ overhang folds back and invades the double-stranded telomeric sequence, 
forming the T-loop and an associated structure, the displacement loop or D-loop (Goytisolo & Blasco, 
2002; Griffith et al, 1999) (Figure 3 a-b). This T-loop structure is sequestering the 3 ́-overhang into a 
higher order DNA structure, preventing the telomere from being recognized as a double-stranded break 
and protecting it from degradation and repair activities (Greider, 1999; Griffith et al, 1999).  
TRF2 is the main component of the shelterin required for T-loop formation and maintenance, 
initiating and stabilizing the interactions between the invading 3’ overhang and the invaded double-
stranded telomere (Doksani et al, 2013; Griffith et al, 1999; Stansel et al, 2001; Yoshimura et al, 2004). 
A recent work using super-resolution fluorescence imaging showed that the depletion of TRF1, RAP1, or 
the POT1 proteins (POT1a and POT1b) had no effect on the frequency of T-loop occurrence (Doksani et 
al, 2013).  
Besides T-loop, the G-rich telomeric strand is also able to form in vitro a secondary DNA 
structure known as G-quadruplexes or G4 (Maizels et al 2006; Fry et al 2007) (Figure 3c). It has 
recently been demonstrated that G4 quadruplexes do form in vivo at G-rich DNA sequences even in the 
context of double-stranded DNA (Lam et al, 2013). However, the in vivo G4 function at telomeres 
remains unclear (Nandakumar & Cech, 2013). G-quadruplexes have been proposed as an alternative 
telomere protective structure when shelterins and thus T-loop have been lost (Lipps & Rhodes, 2009; 
Nandakumar & Cech, 2013). G-quadruplexes are piles of G-quartets, planar assemblies of four 
Hoogsteen-bonded guanines, with the guanines derived from one or more nucleic acid (Sundquist & 
Klug, 1989; Williamson et al, 1989). Unlike T-loop, G-quadruplexes form spontaneously: they do not 
require any shelterin to be formed and stabilized (Sundquist & Klug, 1989; Williamson et al, 1989). In 
addition, shelterins do not bind to the portion of the telomere that acquires a G-quadruplex structure 
(Yanez et al, 2005).  
 
Figure 3. The structure of the T-loop and G-quadruplexes. A) The T-loop structure. From de Lange et al., 2009. B) 
Visualization of mammalian T-Loop in HeLa cells, by electron microscopy, from Griffith et al 1999.  C) G4 quadruplex 
structures (Nelson et al, 2004).  
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1.3. The end replication problem leads to telomere shortening  
The end of linear DNA molecules cannot be replicated by standard DNA polymerases. In effect, 
standard polymerases can only add bases to the 3’ end of a newly synthesized strand and move 3’-5’ 
along the parental template strand. Taking into account that DNA strands are oriented antiparallely, this 
forces a continuous replication at one of the parental strands and a discontinuous replication at the 
other. The continously-replicated parental strand gives rise to the newly synthetized “leading strand”, 
while the discontinously-replicated parental strand gives rise to the “lagging strand”, that is replicated by 
fragments called the Okazaki fragments (Okazaki et al, 1967). The so-called “end-replication problem” 
lies on the antiparallel characteristic of DNA strands combined with the fact that DNA polymerases can 
only polymerize in 5’-3’ direction and need thereby a primer and a template to be able to start the 
polymerization of the complementary sequence. During replication, those primers are firstly synthesized 
by the primase, a specialized enzyme that can polymerize without a primer. This allows DNA 
polymerase to polymerize the rest of the DNA molecule. After this polymerization, primers are degraded 
and the resulting gaps are filled by DNA polymerase, using the 3’end of the previously synthesized DNA 
as a primer. At the 3’ overhang of the lagging strand, the complementary newly synthesized strand has 
a 5’ gap (generated by the degradation of the primer) that can not be filled by DNA polymerase, because 
it lacks a primer to do so (Figure 4). As a consequence, during each cell division cycle, telomeres 
shorten (Harley et al, 1990; Hastie et al, 1990).  
Another factor that has been proposed to contribute to telomere shortening is the de-regulation 
of the enzymatic resection of telomeric 5’ ends (Huffman et al, 2000; Longhese et al, 2010). 5’ resection 
is a post-replicative processing that occurs at both lagging and leading strand, and involves several 
enzymatic activities that result in the generation of the 3’ overhang at telomeres (Wu et al, 2012a). 5’ 
resection at mammalian telomeres is mediated by EXO1 and Apollo nucleases, whose activity and 
recruitment is regulated by TRF2 and POT1 (Wu et al, 2012a). De-regulation of 5’ resection can lead to 
hyper-resection and has been proposed to cause telomere shortening (Huffman et al, 2000; Longhese 
et al, 2010; Wu et al, 2012a). However, this enzymatic activity is also necessary for telomere 
maintenance, because it results in the formation of the 3’ overhang that is needed for telomere 
elongation. 
 
2. Telomere length maintenance 
 
2.1. De novo synthesis by telomerase 
Telomeres can be elongated by a specialized DNA polymerase, the telomerase (Blackburn, 
2001; Greider & Blackburn, 1985). Telomerase is a nucleo-protein complex whose essential 
components are a reverse transcriptase subunit or Tert and an RNA template or Terc (Cohen et al, 
2007; Chen et al, 2000; Feng et al, 1995; Greider & Blackburn, 1985; Meyerson et al, 1997). Other 
components are required for the scaffolding and stabilization of the complex, such as the dyskerin 1 or 
DKC1 (Cohen et al, 2007; Mitchell et al, 1999). 
Following conventional replication of telomeres by DNA polymerase, and generation of the 3’ 
overhang, telomerase will elongate de novo the 3’ overhang by addition of telomeric repeats (Blasco et 
al, 1995; Greider & Blackburn, 1985) (Figure 4). Telomere elongation by telomerase is regulated by cell 
cycle, being coupled to DNA replication and occuring at late S phase (Marcand et al, 2000).  
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Telomerase activity compensates for telomere shortening in those cells where it is expressed, 
such as embryonic stem cells, germ cells, adult stem cells, as well as the majority of late stage human 
cancers (Blasco, 2005; Deng & Chang, 2007; Hiyama & Hiyama, 2007; Shay & Bacchetti, 1997; Shay & 
Wright, 2010). However, in most somatic cells of the adult organism the telomerase activity is low or 
absent, in any case not enough to compensate for telomere loss, resulting in telomere shortening 
(Blasco, 2005; Collins & Mitchell, 2002; Flores et al, 2008; Hiyama & Hiyama, 2007; Wright et al, 1996). 
 
 
Figure 4. How telomeres are replicated. Top left panel: Schematic depiction of the progression of 
replication fork and the newly synthesized leading and lagging strands. Bottom: schematic depiction of 
telomeres, showing the steps that follow DNA polymerase synthesis. 
 
 
2.2. Alternative lengthening of telomeres (ALT) 
On top of telomerase activity, other alternative mechanisms exist to elongate the telomeres, 
collectively known as ALT, and described for the first time in tumors (Bryan et al, 1997). Indeed, 10-15% 
of tumors show ALT (Bryan et al, 1997). It is currently accepted that ALT is based on homologous 
recombination and that it gives rise to heterogeneous telomere length, multi-telomere clusters and 
associated pro-myelocytic leukemia protein bodies (PML bodies), which contain (TTAGGG)n DNA and 
telomere-binding proteins (Bryan et al, 1995; Dunham et al, 2000; Yeager et al, 1999). However, the 
molecular mechanisms initiating ALT and the driving the recombination are not fully understood and 
several models exist (Cesare & Reddel, 2010; Cho et al, 2014). Recently, it has been demonstrated that 
a DSB response at ALT telomeres triggers long-distance movement and clustering of chromosome 
ends, resulting in homology-directed telomere synthesis (Cho et al, 2014). This phenomenon requires 
two proteins that are essential for homologous chromosome synapsis during meiosis: the Rad51 
recombinase and the Hop2-Mnd1 heterodimer (Cho et al, 2014). This study indicated that there is a 
specialized homology searching mechanism in ALT-dependent telomere maintenance and provided a 
molecular basis underlying the preference for recombination between non-sister telomeres during ALT. 
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2.3. Role of shelterin in telomere length maintenance 
Shelterin regulates telomere length by several means, the first being a regulation of the 
telomerase access to the telomere. Indeed, the amount of shelterin bound telomeres has been proposed 
to regulate telomere length through the T-loop structure, in a model known as the “protein counting 
model” (Marcand et al, 1997). A higher amount of shelterin promotes T-loop formation, and therefore a 
closed conformation of the telomere that does not allow the access of telomerase. When telomeres 
shorten, they progressively loose shelterin and the T-loop structure becomes more relaxed or 
desappears, allowing the access of telomerase. This feedback loop would explain how telomeres 
maintain their length in the cells that possess telomerase activity, and why the shortest telomeres are 
preferentially elongated (Marcand et al, 1999). Supporting this model, several shelterins have been been 
proposed to act as negative regulators of telomere length. Namely, it has been shown that both TRF1 
and TRF2 are negative regulators of telomere length when overexpressed (Blanco et al, 2007; Munoz et 
al, 2009; van Steensel & de Lange, 1997). However, this model is quite simplistic, and it is nowadays 
known that both TRF1 and TRF2 do not only regulate telomere length by the stabilization of the closed 
structure of the telomere. TRF1 has been proposed to exert its negative regulation in part through its 
interaction with POT1, that regulates negatively the access of the telomerase to the telomere (Loayza & 
De Lange, 2003). Indeed, POT1 has a very high affinity for the 3’ overhang, coats it completely and thus 
competes with telomerase to bind it (de Lange, 2005; Kelleher et al, 2005). Regarding TRF2, it promotes 
the formation of the T-loop closed conformation of the telomere, but it also regulates several enzymatic 
activities implicated in the T-loop unfolding that is needed during replication, namely WRN and BLM 
helicase activity (Doksani et al, 2013; Gilson & Geli, 2007; Opresko et al, 2005; Opresko et al, 2002). 
TRF1 has also been proposed to collaborate in the T-loop and G4 unfolding needed during replication 
by recruiting the RTEL1 and BLM helicases to telomeres (Sfeir et al, 2009; Vannier et al, 2012). 
Besides regulating telomerase access through the cited telomere structural changes, part of 
shelterin is also directly controlling the activity of telomerase at telomeres: TRF1 recruits the telomerase 
inhibitor PINX1 to telomeres, inhibiting telomere elongation (Soohoo et al, 2011; Zhou & Lu, 2001). It 
has been demostrated in vivo that TPP1 recruits the telomerase to the telomere, and in vitro, that the 
complex TPP1-POT1 increases telomerase activity and processivity (Tejera et al, 2010; Wang et al, 
2007; Xin et al, 2007). POT1 has therefore a dual role in telomere length regulation: before telomerase 
binds to the overhang, POT1 exerts an inhibitory function on telomerase binding. However, once the 
telomerase has been recruited by TPP1 to the 3’ overhang, the complex TPP1-POT1 becomes a 
positive regulator of telomere length. It has been proposed that telomerase binding to TPP1 would 
disrupt shelterin complex in a manner that leaves TPP1-POT1 associated with the chromosome end, 
where it then stimulates telomerase activity (Baumann & Price, 2010).  
In addition to a direct control over telomerase activity, several shelterins have been shown to 
regulate the 5’ resection of the telomere. The de-regulation of telomeric 5’ resection can cause 
hyperresection and has been linked with telomere shortening (Huffman et al, 2000; Longhese et al, 
2010; Wu et al, 2012a). POT1 has been proposed to limit 5’ ressection by inhibiting the activity of Apollo 
nuclease at telomeres, protecting them from hyperesection (Wu et al, 2012a). An in vivo evidence of this 
can be found in Potb-deficient mouse models, that show a hyper-long 3’ overhang (He et al, 2009; 
Hockemeyer et al, 2006; Hockemeyer et al, 2008; Wu et al, 2006). TRF1 and TRF2 are negative 
regulators of telomere length in part through the control of the activity at telomeres of the exonuclease 
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XPF, an enzyme involved in DNA repair pathways and implicated in telomere degradation (Munoz et al, 
2009; Munoz et al, 2005).  
With all those evidences, one would expect that Trf1 deletion cause a change in telomere 
length. However, the deletion of Trf1 do not have a major impact on the overall telomere length in 
mouse models, suggesting that TRF1 alone is not essential for telomere length maintenance and has a 
more important role in telomere protection and in the replication of telomeric DNA (Martinez et al, 2009b; 
Sfeir et al, 2009).   
 
3. Telomere dysfunction, DNA repair and DNA damage response 
 
When telomeres have reached a critically short length or have lost shelterin proteins, they are 
unable to form the T-loop (de Lange, 2005; Yoshimura et al, 2004), thereby losing their ability to protect 
the end of the chromosomes: telomeres become dysfunctional. In this situation, telomeric DNA turns into 
an unprotected DNA end, and becomes indistinguishable from a double-strand break (DBS). DSBs are 
detected by the DNA damage response (DDR), which is a network of cellular pathways that sense, 
signal and repair DNA lesions. 
Functional telomeres exert their end-protection function by inhibiting the activation of the DDR 
that would be activated at a normal DSB. Precisely, a recent work shows that functional telomeres are 
inhibiting six distinct DDR pathways: the 5’ resection pathway, the homology-directed repair pathway 
(HDR), the classical non-homologous end-joining pathway (c-NHEJ), the alternative non-homologous 
end-joining pathway (alt-NHEJ), and the signalling pathways of the kinases ATM (Ataxia Telangiectasia 
Mutated) and ATR (ATM and Rad3-related) (Sfeir & de Lange, 2012) (Figure 5). At functional 
telomeres, the main DDR-repressing shelterins are TRF2 and POT1: TRF2 is directly inhibiting ATM and 
POT1 is directly inhibiting ATR (Denchi & de Lange, 2007; Karlseder et al, 1999; Karlseder et al, 2004). 
In addition, TRF2 and POT1 have been shown to directly inhibit c-NHEJ and HDR (Celli & de Lange, 
2005; Celli et al, 2006; Palm et al, 2009). Of note, other shelterins can prevent ATM/ATR activation, but 
to a lesser extent and in a more indirect way than TRF2/POT1. Namely, TRF1 represses ATR activation 
by protecting from replication fork stalling and thus from DNA single-stranded breaks occurrence during 
telomere replication (Martinez et al, 2009b; Sfeir et al, 2009).  
 
 
Figure 5. Functional telomeres inhibit the activation of DNA damage response pathways.  
The six DDR pathways inhibited by shelterin at functional telomeres. From De Lange et al. 2012.  
 
 
A current model for how dysfunctional telomeres activate a DDR is based on the notion that 
dysfunctional telomeres harbor insufficient amounts of shelterin to inhibit DDR activation (Palm & de 
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Lange, 2008; Smogorzewska et al, 2000). This model is supported by the fact that abrogation of certain 
shelterin components like TRF1 can elicit a DDR in the absence of telomere shortening (Martinez et al, 
2009b). DDR activation has important consequences for the outcome of the cell: activation of ATM/ATR 
leads to cell cycle arrest or apoptosis, NHEJ induces chromosome fusions and HDR can promote 
sequence exchanges. For that reason, the repression of DDR is tightly regulated. 
 
3.1. Activation of ATM/ATR pathways  
ATM and ATR kinases are among the earliest transducers known to initiate the DDR signalling 
cascade at damage sites. This cascade ultimately results in the activation of p21 and p53, leading to 
senescence/apoptosis (Takai et al, 2003; von Zglinicki et al, 2005). Once activated, the kinases ATM, 
ATR and DNA-PK (the main mediator of c-NHEJ) orchestrate the whole DDR response, by 
phosphorylating multiple substrates implicated in the DDR (Figure 6a-b and 7).   
The current proposed mechanism for ATM/ATR activation at dysfunctional telomeres is the 
following (de Lange, 2009) (Figure 6a-b). When TRF2 levels are not enough to maintain T-loop 
structure, T-loop opens, and chromosome ends become a double-stranded DNA break that can be 
sensed and bound by the MRN complex, formed by MRE11, RAD50 and NBS1 (de Jager et al, 2001). 
MRN activates then ATM (Lee & Paull, 2007). In contrast, ATR needs unprotected single-stranded DNA 
to be activated (Cimprich & Cortez, 2008). Single-stranded unprotected DNA is bound by replication 
protein A or RPA (a single-stranded DNA-binding protein), which in turn recruits ATR, through the 
adaptor protein ATRIP (Zou & Elledge, 2003). At functional telomeres, POT1 has been proposed to 
inhibit the activation of ATR pathway by binding with high affinity to the telomeric 3’ overhang and thus 
preventing RPA from binding the overhang, in a competitive manner (Denchi & de Lange, 2007). At 
telomeres that do not harbor enough amounts of POT1, RPA will be able to bind to the overhang and 
activate ATR pathway (Barrientos et al, 2008). Another reason that can contribute to ATR activation at 
POT1-depleted telomeres is 5’ resection. Indeed, POT1 depletion will result in a release of the inhibition 
on 5’ resecting enzymes like EXO1 (Wu et al, 2012a). 5’ exonucleases will then attack the 5’ telomeric 
end, resulting in a longer 3’ overhang and thus more substrate for RPA binding and ATR activation. 
 
 
Figure 6. Activation of ATM/ ATR pathways at dysfunctional 
telomeres. A) Activation of NHEJ and ATM pathways upon TRF2 loss. B) 
Activation of ATR pathway upon POT1 loss. From de Lange et al., 2009. 
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ATM has an essential role in signalling from DSBs arising from ionizing radiation (IR) through a 
CHK2-dependent pathway, while ATR is typically involved in signalling from replication-linked SSBs 
through the CHK1 kinase (Liu et al, 2000). Recent findings, however, have demonstrated an active 
cross talk between ATM and ATR signalling pathways in response to DNA damage (Matsuoka et al, 
2000; Murga et al, 2009). That is to say that if one of the pathways is activated (either ATM/CHK2 or 
ATR/CHK1), it can activate the other. Both CHK1 and CHK2 can activate p53 upon DNA damage (Shieh 
et al, 2000) and are important for cell cycle checkpoints. However, while CHK1 is crucial for intra-S and 
S/G2 transition, CHK2 is more important for G1/S checkpoint (Hirao et al, 2002; Liu et al, 2000; Takai et 
al, 2002; Takai et al, 2000).  
 
 
Figure 7. The interaction between the different pathways of the DNA damage response.  
 
 
3.2. Activation of non-homologous end-joining repair pathways: c-NHEJ and alt-NHEJ  
DDR comprises several DSBs repair pathways: those are mainly the classical and alternative 
non-homologous end joining (c-NHEJ and alt-NHEJ), and the homology-directed repair (HDR). NHEJ is 
the more frequent mechanism to repair dysfunctional telomeres in mammals during G1 (Smogorzewska 
et al, 2002). Globally, NHEJ is an error-prone repair mechanism and generates chromosome fusions.  
Classical NHEJ (c-NHEJ) is mainly mediated by the complex DNA-PK, composed of the 
subunits Ku70/80 and DNA-PKcs (Yaneva et al, 1997) (Figure 8). Ku70/80 exhibits sequence-
independent affinity for double-stranded termini (Blier et al, 1993; Falzon et al, 1993; Hsu et al, 2000). c-
NHEJ is triggered when Ku70/80 recognizes a DSB and binds to it (Walker et al, 2001). Ku70/80 recruits 
then the DNA-dependent protein kinase catalytic subunit or DNA-PKcs (Gottlieb & Jackson, 1993) to 
form the activated DNA-PK (Calsou et al, 2003). It has been proposed that at capped telomeres, DNA-
PK proper binding to DSBs and DNA-PK activation is inhibited by its interaction with the shelterin protein 
TRF2, preventing c-NHEJ (Bombarde et al, 2010; Ribes-Zamora et al, 2013; Sfeir & de Lange, 2012). 
Once bound to the broken ends, DNA-PKcs become activated via auto-phosphorylation, dissociate from 
the DSBs, and can phosphorylate other targets belonging to DDR including RPA, WRN, Artemis, and 
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H2AX (Collis et al, 2005). The activated DNA-PK is going to promote the association with another DNA-
PK-bound chromosome end (DeFazio et al, 2002), and ultimately mediate the recruitment of the 
resolution complex XRCC4/XLF/ligase IV (Calsou et al, 2003). XRCC4 exonuclease is going to cleave 
the damaged/ exposed 3’ telomeric overhang to generate blunt ends (Zhu et al, 2003), followed by 
ligation of chromosome ends by ligase IV (Celli & de Lange, 2005; Espejel et al, 2002a; Espejel et al, 
2002b; Smogorzewska et al, 2002). Other DNA ends processing proteins have been involved in c-NHEJ 
like the DNA nuclease Artemis (Ma et al, 2002). c-NHEJ is ligase IV and Ku70/80-dependent (Celli & de 
Lange, 2005; Celli et al, 2006). 
An alternative end-joining mechanism or alt-NHEJ has been described to be enhanced in the 
absence of proficient c-NHEJ (Nussenzweig & Nussenzweig, 2007; Riballo et al, 2004; Wang et al, 
2006). Several DNA repair proteins have been implicated in alt-NHEJ: DNA ligase IIIα/XRCC1, 
poly(ADP) ribose polymerase-1 (PARP-1), the MRN complex, WRN and CtlP (Audebert et al, 2004; 
Cheng et al, 2011; Lee-Theilen et al, 2011; Rass et al, 2009; Robert et al, 2009; Wang et al, 2005; 
Wang et al, 2006; Zhang & Jasin, 2011). Compared to c-NHEJ, the key features of alt-NHEJ pathway 
are that the repair junctions are characterized by larger deletions, insertions, and a much higher 
frequency of chromosomal translocations (Nussenzweig & Nussenzweig, 2007). Alt-NHEJ exists at low 
levels in normal cells (Sallmyr et al, 2008), and its upregulation has been linked with cancer. Indeed, 
recent studies suggest that oncogenes critical in the pathogenesis of leukemias directly or indirectly 
downregulate steady state levels of c-NHEJ proteins, and in concert, upregulate key alt-NHEJ proteins, 
leading to an increase in the frequency of deletions and translocations, which likely drive genomic 
instability, disease progression or resistance to treatment (Chen et al, 2008; Li et al, 2011; Sallmyr et al, 
2008). 
 
3.3. Activation of the 5’ resection pathway and homology directed repair pathway (HDR) 
HDR is an error-free repair based in the recombination of homologous repeated sequences, 
that was described for the first time in yeast (Szostak et al, 1983). HDR is not deleterious but is less 
frequent: it takes place at S or G2 phases of the cell cycle because it requires sister-chromatid 
sequences as the template for homologous recombination (San Filippo et al, 2008).  
The first step in HDR is the 5’ resection of the DSBs to form the single-stranded DNA tails that 
allow annealing of the ends or strand invasion and homology search during HDR (Symington, 2014). 5’ 
resection occurs also at newly replicated functional telomeres but, interestingly, this process is different 
from the resection occurring at DSBs (Longhese et al, 2010). 5′ end resection at DSBs is mainly 
mediated by the BLM helicase and the CtIP, and EXO1 nucleases (Gravel et al, 2008; Mimitou & 
Symington, 2008; Zhu et al, 2008). Interestingly, CtIP phosphorylation by ATM is necessary for its 
recruitment to DBS by MRN complex, and for the initiation of CtIP-mediated 5’ resection (Sartori et al, 
2007; You et al, 2009). The ssDNA generated by 5’ resection is first coated by RPA (Sugiyama et al, 
1997), which is subsequently replaced by Rad51, loaded by BRCA2 (Tarsounas et al, 2003). Rad51, 
together with the help of other associated proteins, forms nucleoprotein filaments that mediate strand 
invasion on the homologous template (Baumann et al, 1996). After strand invasion, the DNA end is 
extended using the intact sequence as a template (McIlwraith et al, 2005). After restoration of any lost 
sequence information, the second end of the broken DNA is captured and the junctions are resolved to 
give a precisely repaired DSB (Pardo et al, 2009) (Figure 8).  
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Figure 8. Classical NHEJ and Homology-directed repair pathways 
(Brandsma & Gent, 2012).  
 
53BP1 and RIF1 have been shown to repress DSB 5’ resection (Bunting et al, 2010; Chapman 
et al, 2013; Zimmermann et al, 2013). In particular, 53BP1 binds to DSBs, is activated by ATM and 
recruits RIF1 to DSBs to repress 5’ resection (Silverman et al, 2004; Zimmermann et al, 2013). By 
repressing 5’end resection, 53BP1 is inhibiting HDR and promoting NHEJ (Bunting et al, 2010). In 
addition, in the context of dysfunctional telomeres 53BP1 is directly promoting c-NHEJ by mediating the 
long-distance interactions between chromosome ends that are necessary for c-NHEJ (Dimitrova et al, 
2008). Indeed, the abrogation of 53bp1 abolishes c-NHEJ pathway and favors HDR at TRF1-depleted 
dysfunctional telomeres (Martinez et al, 2012).   
c-NHEJ, alt-NHEJ and HDR are mutually exclusive: once DSBs are bound by Ku70/80, alt-
NHEJ and HDR are inhibited (Fattah et al, 2010; Sfeir & de Lange, 2012). Indeed, alt-NHEJ is 
suppressed by ligase IV and Ku70/80 (Sfeir & de Lange, 2012). Reciprocally, 5’ resection promotes 
HDR and inhibits Ku70/80 binding and thus c-NHEJ (Langerak et al, 2011; Sun et al, 2012). 
 
4. Telomere and telomerase function in cancer and aging 
 
4.1. Telomere shortening is one of the factors that limit lifespan 
In 1961 Hayflick and Moorhead observed that human fibroblasts entered a state of irreversible 
growth arrest called replicative senescence upon serial passaging in vitro, whereas cancer cells did not 
(Hayflick & Moorhead, 1961). They hypothesized the existence of cellular factors (known as the 
“Hayflick factors”), which loss through consecutive cell divisions would impede that normal cells 
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proliferate indefinitely.  
Adult stem cells are responsible for maintaining the regenerative potential of the tissues, 
replacing the senescent or dead cells. This maintenance is especially important for the high renewal 
tissues like the gastrointestinal intestine epithelium and the haematopoietic system (Rando, 2006). The 
progressive loss of the regenerative potential of tissues will ultimately impair tissue function, resulting in 
organism aging and death (Collado et al, 2007). Telomerase is expressed in the germline and most 
adult stem cell compartments (Allsopp et al, 1992; Flores et al, 2008; Hiyama & Hiyama, 2007; Kim et al, 
1994). However, telomerase activity is not sufficient to maintain telomere length and therefore telomere 
shortening takes place with age in all the somatic cells of the tissues –in both differentiated cells and 
adult stem cells (Blasco, 2007b; Chiu et al, 1996; Flores et al, 2008; Harley et al, 1990; Hiyama & 
Hiyama, 2007; Vaziri et al, 1994). This progressive telomere shortening is one of the molecular 
pathways or “Hayflick factors” underlying organism aging (Blasco, 2007b; Lopez-Otin et al, 2013; 
Rudolph et al, 1999).  
 
4.2. Some premature-aging pathologies show short/uncapped telomeres 
Supporting the notion that telomere shortening is one of the main mechanisms underlying 
aging, mutations in the different components of telomerase as well as in some components of the 
shelterin complex have been linked to rare human genetic degenerative diseases, the so-called 
telomere syndromes (Armanios & Blackburn, 2012; Donate & Blasco, 2011). These telomere syndromes 
are associated with the presence of short or dysfunctional telomeres, exhibiting a characteristic failure in 
the regenerative capacity of tissues, resulting in premature aging and death (Armanios & Blackburn, 
2012; Donate & Blasco, 2011).  
Precisely, mutations in any of the components of telomerase (TERT, TERC or DKC1) can lead 
to a severe form of bone marrow deficiency known as Dyskeratosis congenita (DC) (Mitchell et al, 1999; 
Vulliamy et al, 2001). DC is characterized by mucosal leukoplakia, nail dystrophy and abnormal skin 
pigmentation (Dokal, 2000). Other examples of telomere syndromes are Aplastic anaemia, Idiopathic 
pulmonary fibrosis and Liver fibrosis (Armanios et al, 2007; Calado et al, 2009; Tsakiri et al, 2007; 
Yamaguchi et al, 2005).  
A second class of premature aging diseases with accelerated telomere shortening present 
mutations in DDR proteins that interact with shelterin components, i.e. Werner’s syndrome (WRN 
mutations), Bloom syndrome (BLM mutations) or Ataxia telangiectasia (ATM mutations) (Blasco, 2005; 
Opresko et al, 2005).  
 
4.3. Telomere shortening and cancer 
Telomeres shorten through the lifespan (Blasco, 2007b; Flores et al, 2008). Critically short 
telomeres activate a checkpoint-dependent cell cycle arrest (Takai et al, 2003; von Zglinicki et al, 2005). 
If an important cell cycle checkpoint gene like p53 or Rb is abrogated in this cellular context, cells can 
escape the growth arrest and start to divide again, the cells become “immortal” (Klingelhutz et al, 1994; 
Shay et al, 1991; Stewart & Bacchetti, 1991). Those cells that bypass senescence would further shorten 
their telomeres and increase their genomic instability, eventually entering a second growth arrest state 
(telomere crisis) when many shortened chromosome ends fuse, resulting in chromosome bridge-
breakage-fusion cycles that almost universally lead to apoptosis (Hackett et al, 2001). The mutagenic 
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potential of this genetic instability can lead to the activation of oncogenes, accelerating the proliferative 
rate of cells -a phenomenon known as oncogenic stress- which in turn could increase the rate of 
telomere shortening and aggravate telomere crisis (Di Micco et al, 2006; Gorgoulis et al, 2005). In 
human cells, these two mechanisms to restrict cell growth -senescence and crisis- are potent anticancer 
protection mechanisms, at least initially (Shay et al, 1991), but also pro-aging mechanisms (Blasco, 
2007b; Lopez-Otin et al, 2013; Rudolph et al, 1999) (Figure 9). Cells can only overcome this telomere 
crisis and survive if they manage to maintain or elongate their telomeres by re-activation of telomerase 
expression or acquisition of alternative telomere lengthening mechanisms (ALT) (Klingelhutz et al, 1994; 
Stewart & Bacchetti, 1991). These confer to the cell the ability to grow continuously (to become 
immortal), which is generally believed to be a critical step in cancer progression (Hanahan & Weinberg, 
2000). Cells that have escaped crisis generally have two defining hallmarks, telomere stability and 
reactivation of telomerase (Kim et al, 1994; Shay & Bacchetti, 1997).  
 
Figure 9. The connection between telomeres, aging and cancer.  
 
 
4.4. Telomerase and shelterin mouse models 
 
4.4.1. Telomerase mouse models 
TERC and TERC telomerase subunits are required for telomere lengthening function (Cristofari 
& Lingner, 2006). In addition, TERT has been described to have extra-telomeric roles independent of 
telomerase activity: TERT has been shown to promote stem cell proliferation in mouse models 
(Gonzalez-Suarez et al, 2001; Sarin et al, 2005), and to act as a transcriptional activator of WNT and 
MYC (Choi et al, 2008; Park et al, 2009), which are two important genes associated with stem cell 
function and cancer.  
The impact of telomerase overexpression on aging was not easy to address because of its 
cancer-promoting effect. Indeed, the constitutive overexpression of telomerase subunit Tert in mouse 
basal skin resulted in improved tissue regeneration but also in slightly increased cancer (Gonzalez-
Suarez et al, 2001). However, combining the overexpression of Tert with the overexpression of p16 and 
p53 tumor suppressors resulted in prolonged mouse lifespan and reduction of aging pathologies, without 
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increasing cancer (Tomas-Loba et al, 2008) 
While telomerase overexpression promotes cancer, telomerase deficiency in Terc-deficient 
mouse models leads to cancer resistance (Gonzalez-Suarez et al, 2000; Lee et al, 1998; Rudolph et al, 
1999). Telomerase abrogation in the context of cancer-prone mouse models, however, has only shown 
anti-tumorigenic activity after several mouse generations of telomerase deficient Terc-/- mice, when 
telomeres reach a critically short length (Chin et al, 1999; Greenberg et al, 1999). A similar scenario has 
been found for chemically induced carcinogenesis, where first generation telomerase deficient mice (G1 
Terc-/- mice), develop tumors at a similar rate than wild-type counterparts, and it is only after five mouse 
generations in the absence of telomerase (G5 Terc-/-) that critically short telomeres effectively impair 
tumor formation (Gonzalez-Suarez et al, 2000). Telomerase-deficient mice Terc-/- are good models to 
study aging, because they show progressive telomere shortening, eventually impairing tissue 
regeneration and leading to tissue atrophy and premature aging phenotypes (Gonzalez-Suarez et al, 
2000; Lee et al, 1998; Rudolph et al, 1999).  
p53 deficiency abrogates the proliferative defects and the tumor suppressor effect of short 
telomeres in Terc-/- p53-/- mice, indicating that p53 is one of the main downstream mediators of the 
cellular response to DDR triggered by short telomeres (Artandi et al, 2000; Chin et al, 1999; Flores & 
Blasco, 2009). It has also been demonstrated that p21 plays a main role in this DDR, because doubly-
deficient Terc/p21 mice show extended survival and lesser proliferative defects than the Terc single-
deficient mice, without increasing the cancer incidence (Choudhury et al, 2007).  
 
4.4.2. Shelterin-deficient mouse models  
The early embryonic lethality of shelterin ubiquitous-deleted mouse models, with the exception 
of Rap1-deficient mice, has impeded to study the role of shelterins in telomere-driven aging (Martinez & 
Blasco, 2010). Recent conditional knock-out mouse models have helped to understand the molecular 
mechanisms of shelterin-induced telomere dysfunction. 
 
4.4.2.1. POT1 mouse models 
POT1 has a main role in the coating and protection of the telomeric 3’ overhang, in the 
repression of DDR and in the regulation of telomerase activity. Indeed, it has been demonstrated that 
the complex TPP1-POT1 augments telomerase processivity through direct interaction with telomerase 
(Latrick & Cech, 2010; Wang et al, 2007; Xin et al, 2007; Zaug et al, 2010).  
In mice, there are two distinct forms of POT1: POT1a and POT1b (Hockemeyer et al, 2006). 
Both are highly homologous and can bind telomeric ssDNA, but they seem to have distinct functions at 
telomeres (Hockemeyer et al, 2006; Wu et al, 2006). POT1a has a more prominent role in the 
repression of the DDR at telomeres while POT1b has a predominant role in the regulation of 3’ overhang 
length by a telomerase-independent mechanism that has been proposed to be the repression of 5’ 
resection (Hockemeyer et al, 2006; Palm et al, 2009; Wu et al, 2006; Wu et al, 2012a). Combined 
deletion of Pot1a and Pot1b resulted in loss of cell viability (Hockemeyer et al, 2006). Deletion of Pot1a 
was embryonic lethal, whereas Pot1b-deficient mice survived until adulthood and presented increased 3’ 
overhang (He et al, 2009; Hockemeyer et al, 2006; Wu et al, 2006). Pot1b-/- Terc+/- mice also survived 
until the adulthood, but showed a further increased 3’ overhang and decreased telomere length, 
developing Dyskeratosis congenita-associated phenotypes (He et al, 2009).  
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4.4.2.2. TPP1 mouse models 
TPP1 has been implicated in the recruitment of the telomerase to the telomere (Tejera et al, 
2010; Xin et al, 2007). Constitutive and ubiquitous deletion of Tpp1 leads to the telomeric loss of POT1a 
and POT1b, recapitulating the effects of the deficiency of this proteins, and thus resulting in embryonic 
lethality (Kibe et al, 2010). A hypomorphic mouse model with decreased TPP1 levels showed low 
survival, developmental defects including growth retardation, sparse body hair and infertility (Keegan et 
al, 2005). The deletion of p53 in this mouse model rescued some of the developmental defects, 
improved survival but also generated an increased incidence of cancer (Else et al, 2009). Conditional 
deletion of Tpp1 in the basal compartment of the skin results in perinatal death, skin degenerative 
pathologies, hyperpigmentation, defective development of the hair follicle and sebaceous glands (Tejera 
et al, 2010). Importantly, the abrogation of p53 in this mouse model rescued those defects, supporting a 
key role for p53 in mediating the proliferative arrest induced by dysfunctional telomeres (Chin et al, 
1999; Feldser & Greider, 2007; Martinez et al, 2009b; Tejera et al, 2010).  
 
4.4.2.3. TIN2 mouse models 
TIN2 has an important role in bridging the double-stranded binding shelterins and single-
stranded binding shelterins. Importantly, it has been reported that TIN2 deficiency generates the loss of 
TRF2 and TPP1 telomere binding and a reduction of TRF1 binding (Frescas & de Lange, 2014; 
Houghtaling et al, 2004; Kim et al, 2004; Takai et al, 2011; Ye et al, 2004a). Accordingly, constitutive 
and ubiquitous deletion of Tin2 results in embryonic lethality (Chiang et al, 2004). 
 
4.4.2.4. RAP1 mouse models 
RAP1 is not required for telomere protective role but under certain circumstances like Ku 
deficiency it prevents telomere recombination by HDR (Martinez et al, 2010; Sfeir et al, 2010). Rap1 
abrogation did not affect the telomeric heterochromatic structure or the telomeric localization of the other 
shelterin components but did increase homologous recombination at telomeres in mouse models (Sfeir 
et al, 2010). RAP1 has been shown to act as a transcriptional modulator by binding to extra-telomeric 
sites (Martinez et al, 2010). Interestingly, RAP1 protects from obesity by directly regulating the 
expression of two important energy homeostasis enzymes: PPARα and PGC1α (Martinez et al, 2013). 
 
4.4.2.5. TRF2 mouse models 
Trf2-deficient mouse models reflect the importance of TRF2 for the inhibition of DDR signalling, 
for telomere length regulation, T-loop formation and thus for telomere protection.  
Trf2 overexpression in the stem cell compartment of stratified epithelia leads to telomere 
shortening through increasing XPF nucleolytic activity at chromosome ends (Munoz et al, 2005), similar 
to what has been reported for the Trf1 overexpression (Munoz et al, 2009; Munoz et al, 2005; 
Smogorzewska et al, 2000). Trf2 overexpression in basal epidermis resulted in an increased incidence 
of skin spontaneous cancer and premature degenerative pathologies (Munoz et al, 2005). p53 
abrogation in this mouse model improved stem cell function and attenuated degenerative pathologies, 
but increased cancer incidence, again underlining the key role of p53 in the DDR mediated by 
dysfunctional telomeres (Stout & Blasco, 2009).  
Constitutive and ubiquitous deletion of Trf2 results in embryonic lethality (Celli & de Lange, 
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2005). Conditional deletion of Trf2 in the stem cell compartment of stratified epithelia generated 
embryonic or perinatal lethality, with an acute induction of DDR and cell death (Martinez et al, 2014). 
Unexpectedly, neither inhibition of the NHEJ pathway by abrogation of 53bp1 nor inhibition of DDR by 
p53 deficiency rescued these severe phenotypes (Martinez et al, 2014). This stands in contrast with 
Tpp1 and Trf1 deficiencies that can be rescued by p53 abrogation, demonstrating a more essential role 
of TRF2 for skin homeostasis.   
 
4.4.2.6. TRF1 mouse models 
In vitro and in vivo studies have demonstrated that TRF1 is required for proper telomere 
replication and thus for the prevention of replication fork stalling and DNA breaks (Martinez et al, 2009b; 
Sfeir et al, 2009). In addition, several lines of evidence point that TRF1 also has an important role in 
mitosis (d'Alcontres et al, 2014; Nakamura et al, 2002; Ohishi et al, 2014). TRF1 levels are cell cycle-
regulated (Shen et al, 1997). TRF1 co-localizes with mitotic spindle and is needed for microtubule 
polymerization (d'Alcontres et al, 2014; Munoz et al, 2009; Nakamura et al, 2002). TRF1 recruits to the 
mitotic spindle topoisomerase II, an enzyme required for the proper resolution of DNA replication 
intermediates, ensuring telomere proper replication and segregation (d'Alcontres et al, 2014). TRF1 also 
collaborates in proper chromosome segregation through its interaction with Aurora B (Ohishi et al, 
2014). Accordingly, cells deficient for TRF1 show aberrant mitosis and anaphase bridges (d'Alcontres et 
al, 2014). 
TRF1 has also been proposed as a marker of pluripotency (Schneider et al, 2013). In the eGFP-
Trf1+/KI  whole-body conditional knock-in mouse model, that expressed TRF1 protein fused to an eGFP 
reporter, TRF1 was found to be specifically enriched in adult stem cell compartments, independently of 
telomere length (Schneider et al, 2013). High TRF1 expression levels correlated with high levels of the 
pluripotency markers NANOG and OCT4 (Schneider et al, 2013). TRF1 was shown to be a direct 
transcriptional target of the pluripotency factor OCT3/4 (Schneider et al, 2013). Finally, TRF1 was shown 
to be required for the reprogramming of mouse fibroblasts into induced-pluripotent stem cells or IPS, as 
well as for the maintenance of IPS pluripotency state (Schneider et al, 2013).  
Similarly to what shown for Trf2, the overexpression of Trf1 in the basal layer of mouse 
epidermis (K5Trf1 mice) has demonstrated that TRF1 is a negative regulator of telomere length through 
the regulation of XPF activity (Munoz et al, 2009; Smogorzewska et al, 2000). Interestingly, K5Trf1 mice 
show increased cancer upon induced carcinogenesis protocols (Munoz et al, 2009).  
As complete Trf1 deletion in mouse leads to early embryonic lethality at the blastocyst stage 
between embryonic days E5-6 (Karlseder et al, 2003), subsequent studies of Trf1 deficiency in vivo 
have been performed in conditional knock-out models. Importantly, depletion of TRF1 does not affect 
significantly the binding of other shelterins to the telomere (Houghtaling et al, 2004; Martinez et al, 
2009b; Sfeir et al, 2009). Conditional deletion of Trf1 in the hematopoietic compartment results in DNA 
damage, senescence, apoptosis and a proliferation compensatory mechanism that ultimately leads to 
stem cell exhaustion and bone marrow failure (Beier et al, 2012). Similarly, the conditional deletion of 
Trf1 in the intestinal stem cell compartment of adult mice (Trf1∆/∆ Villin-CreERT2+/T mouse model) 
generates increased DNA damage and apoptosis, decreased density of intestinal crypts, atrophic villi 
and weight loss (Schneider et al, 2013). Trf1∆/∆ Villin-CreERT2+/T mice show a compensatory 
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proliferation increase to counter stem cell loss, recapitulating  what has been seen in the Trf1-deficient 
bone marrow model (Beier et al, 2012; Schneider et al, 2013). 
Conditional deletion of Trf1 in mouse stratified epithelia (Trf1Δ/Δ K5Cre mice) leads to perinatal 
lethality and severe skin proliferative defects, which are concomitant with rapid induction of telomere-
originated DNA damage and activation of the p53/p21 pathways (Martinez et al, 2009b). Deletion of Trf1 
induces phosphorylation of both the ATR and ATM downstream kinases CHK1 and CHK2, respectively, 
suggesting that both checkpoint kinases may be important to mediate telomere dysfunction owing to 
TRF1-mediated telomere uncapping (Martinez et al, 2009b; Sfeir et al, 2009). In line with this, inhibition 
of either ATM/ATR kinases in Trf1-deficient MEFs can significantly rescue DNA damage in vitro 
(Martinez et al, 2009b). Deletion of p53 in Trf1∆/∆ K5Cre mice rescues Trf1-associated phenotypes but 
leads to increased carcinogenesis, indicating that p53 is also a main mediator of the DDR induced by 
uncapped telomeres (Martinez et al, 2009b).  
 
4.5. Telomeres and human cancer  
 
Telomerase and the shelterin proteins have been reported to be deregulated in human cancer 
(Artandi & DePinho, 2010; Blasco, 2005; Martinez & Blasco, 2010; Shay & Wright, 2011). It is widely 
accepted that telomerase re-activation in cancer confers a growth advantage, and is required for cancer 
progression (Hanahan & Weinberg, 2000). To maintain a minimum functional telomere length, 80-90% 
of human tumors reactivate telomerase (Joseph et al, 2010; Kim et al, 1994; Shay & Bacchetti, 1997), 
and the remaining activate ALT to maintain telomeres (Bryan et al, 1997). Supporting a role of 
telomerase deregulation in human cancer, single nucleotide polymorphisms in the locus of human 
hTERT have been associated with various malignancies, including glioma, lung cancer, urinary bladder 
cancer, melanoma, and breast cancer, among others (Bojesen et al, 2013; Garcia-Closas et al, 2013; 
Horn et al, 2013; Huang et al, 2013; McKay et al, 2008; Melin et al, 2012; Mocellin et al, 2012; Petersen 
et al, 2010; Rafnar et al, 2009; Shete et al, 2009; Wang et al, 2008). These findings lead to the 
development of telomerase-based therapeutic strategies for cancer treatment (Buseman et al, 2012). 
Regulation of telomerase activity and expression occurs at many levels, including transcription, 
alternative splicing, chaperone-mediated folding, phosphorylation, nuclear translocation of each subunit, 
assembly of the telomerase complex, and its accessibility to telomeres (Collins & Mitchell, 2002). Cancer 
therapies targeting telomerase that are currently being tested in clinical trials include telomerase 
inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies (Buseman et al, 
2012). Namely, several oligonucleotides have been designed to hybridize to the 11 bp human 
telomerase RNA component (hTR) and act as competitive telomerase inhibitors (not antisense targeting 
messenger RNA), preventing its binding to the telomerase hTERT component (Herbert et al, 2002; Shay 
& Wright, 2005). An example of compound that has been developed is GRN163L, currently known as 
Imetelstat (Dikmen et al, 2005). Imetelstat is now being tested in phase I and II in cancer clinical trials, in 
combination with conventional chemotherapy or alone (Buseman et al, 2012; Marian et al, 2010; 
Molckovsky & Siu, 2008). Regarding telomerase-based immunotherapy, several strategies have also 
been developed and many are in advanced clinical trials, making this a rapidly-progressing field of anti-
telomerase cancer therapy (Bernhardt et al, 2006; Brunsvig et al, 2006; Liu et al, 2010; Vonderheide, 
2007; Vonderheide et al, 2004). In brief, anti-telomerase immunotherapy sensitizes immune cells to 
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tumor cells expressing hTERT peptides as surface antigens, directing the patient’s own immune system 
to target and kill telomerase positive tumor cells (Liu et al, 2010; Vonderheide et al, 1999). The immune 
response can be induced by exposure to antigen presenting cells that either overexpress immunogenic 
hTERT fragments (Su et al, 2005) or have been pulsed with immunogenic hTERT peptides. To date, 26 
different hTERT peptides have been utilized to elicit an antitelomerase immune response (Liu et al, 
2010). Regarding telomerase-driven virotherapy, a strategy that has being developed uses the delivery 
of adenoviral vectors containing the sequence of “suicide genes” like TRAIL or caspase 6 under the 
promoter of telomerase, thus inducing cell death in telomerase-positive cells (Katz et al, 2003; Komata 
et al, 2001). Another telomerase-driven adenoviral approach directs the replication of a lytic adenovirus 
in telomerase-positive cells (Lanson et al, 2003), and has already proven anti-tumor activity in phase I 
trials (Nemunaitis et al, 2010). The combination of telomerase-driven adenoviral delivery with 
radiotherapy or chemotherapy is also being studied (Kondo et al, 2010; Liao et al, 2009).   
In contrast to telomerase, the role of shelterin in human cancer remains poorly studied. POT1 
has been shown to be one of the most frequently mutated genes in chronic lymphocytic leukemia, 
correlating with a high incidence of chromosome abnormalities (Ramsay et al, 2013). In melanoma, 
POT1 presented loss-of-function mutations in several affected families (Robles-Espinoza et al, 2014). 
TRF2 expression was elevated in human skin carcinomas (Munoz et al, 2005). TRF2 is overexpressed 
in several other types of cancers, such as leukemia, breast cancer, hepatocarcinoma and lung cancer 
(Bellon et al, 2006; Matsutani et al, 2001; Oh et al, 2005). Similarly to TRF2, TRF1 is over-expressed in 
several human cancers like gastric cancer (Matsutani et al, 2001), hepatocarcinoma (Oh et al, 2005), T-
cell and acute lymphobastic leukemia (Bellon et al, 2006; Ohyashiki et al, 2001), and in squamous cell 
carcinoma (Fujimoto et al, 2003).  
 
5. Lung cancer  
 
5.1. Human non-small cell lung cancer 
Human lung cancer is the leading cause of cancer related deaths worldwide (Siegel et al, 2012). 
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers (Herbst et al, 2008). The overall 
5-year survival rate is of only 15%, largely due to the long-term ineffectiveness of current therapies and 
frequent late stage at time of diagnose (Siegel et al, 2012). 
The discovery that distinct subsets of cancers harbor specific driver mutations in genes that 
encode signalling proteins that are crucial for cellular proliferation and survival constitutes a promising 
strategy to develop anti-cancer therapies. Targeting the activity of these mutant proteins can lead to cell 
death and therapeutic benefit. This finding serves as the basis for the concept of oncogene addiction 
(Weinstein, 2002), implying that tumors have Achilles heels that can be targeted with specific agents. 
In NSCLC, a number of driving mutations have been identified, including epidermal growth 
factor receptor (EGFR) mutations, KRAS mutations, HER2 mutations and EML4-ALK translocations. 
Mutations in the p53 tumor suppressor gene are common in NSCLC, occurring in approximately 50% of 
the cases, while activating mutations in the K-Ras proto-oncogene are found in 30% of NSCL (Chiba et 
al, 1990; Rodenhuis et al, 1988). However, despite a lot of research being carried out, no specific 
treatment has been discovered for KRAS-induced NSCLC, unlike other mutation-driven lung cancers 
like ALK-, EGFR-, or HER2-driven (Choi et al, 2010; Li et al, 2008; Maemondo et al, 2010; Ou et al, 
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2010). In recent years, KRAS mutations in NSCLC have been correlated with non-responsiveness to 
EGFR inhibitors and systemic chemotherapy (Adjei, 2001; Massarelli et al, 2007; Pao et al, 2005). For 
all these reasons, KRAS-driven lung cancers remain poorly understood and are interesting to study.   
 
5.2. Lack of therapies targeting K-RAS 
K-RAS belongs to RAS family of GTPases, like H-RAS and N-RAS. GTPases are proteins that 
can bind GTP (becoming active) and hydrolyze it to GDP (becoming inactive). RAS is an extremely 
challenging direct drug target due to the inherent difficulties in disrupting its activation, localization and 
function (Mattingly, 2013). Until recently, K-RAS has been widely considered undruggable (Berndt et al, 
2011). 
RAS most frequent mutations consist in a loss of the enzymatic hydrolysis activity: mutated K-
RAS is unable to hydrolyze the GTP bound to it, and thus remains constitutively active (Gibbs et al, 
1984). Constitutively activated RAS generates a persistent stimulation of downstream signalling 
pathways that drive many of the hallmarks of cancer like sustained proliferation, metabolic 
reprogramming, anti-apoptosis, remodelling of the tumor microenvironment, evasion of the immune 
response, cell migration and metastasis (Pylayeva-Gupta et al, 2011). To target the RAS mutated 
proteins, it would be necessary to re-activate their GTPase enzymatic activity, or to prevent their binding 
to GTP, which is almost impossible due to the strong affinity of GTP for RAS (Young et al, 2009). For 
that reason, it has been tried to inhibit RAS in more indirect ways. Namely, a strategy that has been 
tested is the inhibition of the farnesyl-transferase, to block RAS maturation and thus to prevent its 
localization in the membrane where it exerts its function. Unfortunately, this approach has proven to be 
ineffective for the K-RAS isoform in pancreatic cancer clinical trials (Cohen et al, 2003; Van Cutsem et 
al, 2004). Likely reasons for this disappointing outcome include the fact that K-RAS can be farnesylated 
through a farnesyl-transferase-independent mechanism that involves another enzyme, the geranesyl-
transferase (Lerner et al, 1997; Sebti & Der, 2003). 
Another important focus of therapies against RAS has been the inhibition of RAS downstream 
pathways, for example, MEK inhibitors (Friday & Adjei, 2008; Zhao & Adjei, 2014). Nowadays, those 
drugs are entering clinic trials (Zhao & Adjei, 2014). However, the complexity of signalling that is driven 
by activated RAS indicates that effective inhibition of oncogenic transduction through this approach will 
be difficult, with resistance being likely to emerge through switch to parallel pathways. Thus, durable 
disease responses will probably require combinatorial block of several downstream targets (Mattingly, 
2013). 
Interestingly, in a recent study the direct inhibition of an oncogenic form of K-RAS has been 
achieved, through an allosteric regulation strategy that favors the GDP-bound conformation of K-RAS 
(Ostrem et al, 2013). 
 
5.3. K-ras lung cancer mouse models 
Recently, several lung cancer mouse models have been generated with the aim of 
recapitulating human NSCLC by using K-Ras mutated alleles like K-RasG12Vor K-RasG12D (Guerra et al, 
2003; Johnson et al, 2001). In particular, the lox-stop-lox-K-RasG12V knock-in mouse model, in which 
endogenous expression of the K-RasG12V oncogene is induced upon Cre recombinase expression, has 
allowed the study of early stages of lung tumorigenesis (Guerra et al, 2003). Precisely, K-RasG12V 
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oncogene is a mutated form of K-ras gene that produces a constitutively activated K-RAS oncoprotein, 
generating a basal activation of ERK/MAPK signalling pathway and thus conferring hyper-proliferative 
properties to specific cell types like lung bronchio-alveolar cells (Guerra et al, 2003). Combination of K-
RasG12D expression with p53 deficiency has also allowed to recapitulate late stage lung cancers, 
including occurrence of invasion, stromal desmoplasia, and metastasis (Jackson et al, 2005). Indeed, 
the lox-stop-lox-K-RasG12V mouse model has been instrumental to test novel therapeutic strategies 
against lung cancer, such as c-RAF, CDK4, and NOTCH (Blasco et al, 2011; Maraver et al, 2012; Puyol 
et al, 2010).   
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1. To address the role of CHK2 in the in vivo signalling of dysfunctional telomeres originated either by 
telomere shortening or by telomere uncapping. For this purpose, we aimed:  
 
-to generate the Terc-/- Chk2-/- and Trf1∆/∆ K5Cre Chk2-/- compound mouse models.  
 
-to study the effect of Chk2 deficiency in the aging and cancer phenotypes associated to 
telomere dysfunction in those mouse models.  
 
 
 
 
2. To study telomere uncapping as a potential target in anti-cancer therapy. To this purpose, we aimed: 
 
 -to generate a conditional deletion of Trf1 in a K-rasG12V lung cancer mouse model in two 
genetic backgrounds: p53-/- and p53+/+. An in vivo follow-up of tumor development and mouse survival, 
as well as a post-mortem histopathological analysis of tumors will be performed. 
 
-to analyze the effect of TRF1 downregulation in the metastatic potential and growth of lung 
cancer cells, in allograft and xenograft experiments. 
 
-to address the impact of Trf1 ubiquitous depletion in the adult organism, with the Trf1lox/lox 
hUBC-CreERT2 mouse model. 
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1. Abordar el papel de CHK2 en la señalización mediada por telómeros disfuncionales originados por 
acortamiento telomérico o por uncapping telomérico. A este fin, quisimos:   
 
-generar los modelos murinos doblemente deficientes Terc-/- Chk2-/- y Trf1∆/∆ K5Cre Chk2-/-. 
 
-en estos modelos murinos, estudiar los efectos de la deficiencia de Chk2 en los fenotipos de 
envejecimiento y cáncer asociados a la disfunción telomérica.  
 
 
 
 
2. Estudiar el uncapping telomérico como una potencial diana terapéutica en la terapia anti-cáncer. 
Para este propósito, nos propusimos:  
 
 -generar una deleción condicional de Trf1 en el modelo murino de cáncer de pulmón K-rasG12V 
en dos fondos genéticos: p53-/- y p53+/+. Se hará un seguimiento in vivo del crecimiento tumoral y de la 
supervivencia de los ratones, así como un análisis histopatológico post-mortem de los tumores. 
 
-analizar el efecto de la disminución de los niveles de TRF1 en el potencial metastásico y 
crecimiento de células de cáncer de pulmón, en experimentos de alotransplante y xenotransplante. 
 
-investigar el impacto de una deleción ubicua de Trf1 en el organismo adulto, con el modelo 
murino Trf1lox/lox hUBC-CreERT2. 
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1. Mouse experimentation 
 
 
1.1. Mouse generation 
Chk2-/- (Hirao et al, 2002), Terc-/- (Blasco et al, 1997) and Trf1lox/lox K5Cre+/T (Martinez et al, 
2009b) strains were inter-crossed to obtain Terc-/- Chk2-/- and Trf1∆/∆ K5Cre Chk2-/- mice, both 
maintained in C57BL/6 genetic background. Chk2-/-  and Terc-/- are whole-body deficient mouse models, 
whereas Trf1lox/lox K5Cre+/T mouse model only presents Trf1 deficiency in the tissues that express keratin 
5 (K5). K5-expressing tissues are mainly the stratified epithelia: the epithelium of the oral cavity, tongue, 
esophagus, vagina, urethra, epidermis, hair follicle and nails (Dhouailly et al, 1989; Moll et al, 1982; 
Nelson & Sun, 1983). In addition, small amounts of K5 have been detected in some transition epithelia 
like the epithelium of the renal pelvis, the urinary bladder and the ureter (Achtstatter et al, 1985). 
Trf1lox/lox (Martinez et al, 2009b), K-Ras+/LSLG12Vgeo (Guerra et al, 2003), and p53-/- (Jackson Labs, 
http://jaxmice.jax.org/strain/002101.html) strains were crossed to obtain Trf1lox/lox K-Ras+/LSLG12Vgeo p53-/- 
mice, of a mixed background.  
To generate Trf1lox/lox hUBC-CreERT2 mice, we crossed our Trf1lox/lox (Martinez et al, 2009b) 
with a mouse strain that carries a ubiquitously expressed, tamoxifen-activated recombinase, hUBC-
CreERT2 mice (Ruzankina et al, 2007). Both strains were maintained in C57BL/6 genetic background.  
For allograft and xenograft experiments, seven-week-old athymic nude females were obtained 
from Harlan (Foxn1nu/nu).  
 
 
1.2. Mouse maintenance 
All mice were maintained at the Spanish National Cancer Center animal facility, under specific 
pathogen-free conditions in accordance with the recommendations of the Federation of European 
Laboratory Animal Science Associations (FELASA). All animal experiments were approved by the 
Ethical Committee and performed in accordance with the guidelines stated in the International Guiding 
Principles for Biomedical Research Involving Animals, developed by the Council for International 
Organizations of Medical Sciences (CIOMS). Along with those guidelines, mice were observed on a 
daily basis by the technicians from the CNIO animal facility and sacrificed in CO2 chamber when they 
presented signs of morbidity or tumors bigger than 1 cm.  
Mice were maintained on a 12-hour light/12-hour dark cycle. During light cycle, white light was 
provided by fluorescent lamps (TLD 36W/840 and TLD58W/840, Philips). Mice had free access to water 
and standard chow diet (18% of fat-based calory content, Harlan Teckland 2018). Trf1lox/lox hUBC-
CreERT2 mice were fed ad libitum for 7 weeks with tamoxifen-containing diet (Tekland CRD 
Tam400/CreER). 
 
 
1.3. Mouse genotyping 
Mouse genotyping was performed by Transnetyx enterprise (Cordova, TN 38016), except for 
Trf1/Chk2 MEFs and Terc locus. Trf1/Chk2 MEFs were genotyped by standard PCR. Terc locus was 
genotyped by southern blot following previously described procedures (Blasco et al, 1997).  
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1.3.1. Transnetyx genotyping 
Transnetyx uses a qPCR based system and Taqman® probe technology to measure the probe 
fluorescence produced as the reaction is occurring, taking measurements up to the 40th cycle of the 
reaction.  A specific set of sequence is targeted with the fluorescent labeled probe.  Signal is produced if 
that sequence is found in the sample being tested and the probe anneals, releasing the fluorophore.  
The following probes were used for the different mouse strains:   
 
CRE – used to test for Cre; targeted to sequence within the Cre gene coding region. 
Forward Primer Sequence: TTAATCCATATTGGCAGAACGAAAACG 
Reverse Primer Sequence: CAGGCTAAGTGCCTTCTCTACA 
Probe Sequence: CCTGCGGTGCTAACC 
 
Terf1-3 MD – used to test for Trf1lox and Trf1Δ; targeted to a sequence unique to the Trf1 recombined 
allele. 
Forward Primer Sequence: GCTATACGAAGTTATTCGAGGTCGAT 
Reverse Primer Sequence: GGTGGCGGCCGAAGT 
Probe Sequence: CTCTAGAAAGTATAGGAACTTC   
 
Terf1-3 WT – used to test for Trf1+; targeted to sequence at the 3’ loxP insertion site. 
Forward Primer Sequence: GAGACGGCGCGAAACC 
Reverse Primer Sequence: GCGGGAGCCAGGACTTC 
Probe Sequence: CCGCTTCCTGTTTGCTG 
 
Chek2-1 KO – used to test for Chk2 deletion; targeted to sequence at the 3’ neomycin-wild type 
junction. 
Forward Primer Sequence: GGTAGAATTGGGCTGCAGGAAT 
Reverse Primer Sequence: GATAACCTTTGACACTGAGCTCTAACA 
Probe Sequence: CCTGAGAAGCTTGATATCG 
 
Chek2-1 WT – used to test for Chk2 wild type allele; targeted to wild type sequence.  
Forward Primer Sequence: GGCCAAGAGACTGAGGTTCTG 
Reverse Primer Sequence: AGACCCCAGACAAGAAGGAATTTTG 
Probe Sequence: ACAGAGCAGCAAACAC 
 
Kras G12V Mu – used to test for KrasG12V mutation; targeted to the site of mutations that cause G12V 
(GT to TA base). 
Forward Primer Sequence: GGCCTGCTGAAAATGACTGAGTATA 
Reverse Primer Sequence: CTGTATCGTCAAGGCGCTCTT 
Probe 1 Sequence: CTACGCCACCAGCTC 
Probe 2 Sequence: CTACGCCTACAGCTC 
 
p53 Null KO – used to test for the deletion of p53 (Trp53tm1Tyj); targeted to sequence at the neomycin-
endogenous junction. 
Forward Primer Sequence: TGTTTTGCCAAGTTCTAATTCCATCAGA 
Reverse Primer Sequence: TTGTAGTGGATGGTGGTATACTCAGA 
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Probe Sequence: ACAGGATCCTCTAGAGTCAG 
 
p53 Null WT – used to test for the wild type allele of p53; targeted to wild type sequence at the 
neomycin cassette insertion site. 
Forward Primer Sequence: GTGAGGTAGGGAGCGACTTC  
Reverse Primer Sequence:  TTGTAGTGGATGGTGGTATACTCAGA 
Probe Sequence: CCTGGATCCTGTGTCTTC 
 
1.3.2. PCR genotyping 
Trf1/Chk2 MEFs were genotyped by standard PCR with the following primers:  
Trf1-Lox: used to test for the unexcised Trf1lox allele. With this pair of primers, the unexcised Trf1lox 
allele gives an amplified band of 0.6 kb whereas the Trf1+ allele gives a 0.5 kb band. 
Forward Primer (E1-F2): 5’ GGATGCTCGACTTCCTCT 3’ 
Reverse Primer (SA-R1): 5’ GCTTGCCAAATTGGGTTGG 3’ 
 
Trf1-KO: used to test for the excised Trf1∆ allele. With this pair of primers, the excised Trf1∆ allele gives 
an amplified band of 0.48 kb whereas the unexcised Trf1lox allele gives an amplified band of 1.5 kb. 
Forward Primer (E1-popout): 5’ ATAGTGATCAAAATGTGGTCCTGGG 3’ 
Reverse Primer (SA-R1): 5’ GCTTGCCAAATTGGGTTGG 3’ 
 
Chk2 WT: used to test for Chk2 wild type allele. 
Forward Primer: 5’ GTGTGCGCCACCACTATCCTG 3’ 
Reverse Primer: 5’ CCCTTGGCCATGTTTCATCTG 3’ 
 
Chk2 KO: used to test for Chk2-deleted allele. 
Forward Primer: 5’ CAGGAGGTGGTGGCTTACTTTA 3’ 
Reverse Primer: 5’ CAAATTAAGGGCCAGCTCATTC 3’ 
 
1.4. Adenovirus intratracheal infection 
Eight to ten week-old Trf1lox/lox K-Ras+/LSLG12Vgeo p53-/- mice, along with their corresponding wild-
type mice, were instillated once with intratracheal adeno-Cre (Gene Vector Core, University of Iowa, 
1x1010 pfu/mL) with 1x108 PFU/mouse of virus after anesthesia by intraperitoneal injection of ketamine 
50 mg/kg combined with medetomidine 1mg/kg (Domitor, Orion Corporation). To wake up the mice after 
the instillation, they were injected with atipemazole 2.5 mg/kg (Antisedan, Orion) and kept under heat 
lamp for 15 min.  
 
1.5. In vivo imaging by computed tomography (CT) and positron-emission tomography (PET) 
Nine weeks after inoculation, Trf1lox/lox K-Ras+/LSLG12Vgeo p53-/- mice along with their 
corresponding wild-type mice were subjected to an in vivo follow-up of tumor growth performed by the 
Imaging Unit of the CNIO. This follow-up was achieved by 6 computed tomographies every 15 days. 
PET was performed 22nd week post-inoculation and the mice were sacrificed (24th week post-
inoculation). 
For CTs, mice were anesthetized with a continuous flow of 1% to 3% isoflurane/oxygen (2 
liters/min), and thorax images were captured with the GE eXplore Locus micro-CT scanner (GE 
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Healthcare). The isotropic resolution of this instrument is 45 µm. The micro-CT image acquisition 
consisted of 400 projections collected in one full rotation of the gantry in approximately 10 min. The 
image acquisition was not respiratory-gated. The X-ray tube settings were 80 kV and 450 µA. The 
resulting raw data were reconstructed to a final image volume of 875 x 875 x 465 slices at 93 µm3 voxel 
dimensions. The reconstructed images were viewed and analyzed with MicroView analysis software (GE 
Healthcare). 
PET analysis was made along with a CT, to localize the lesions in the lung. Images were 
acquired using eXplore Vista PET–CT (GE Healthcare). Mice were fasted for a minimum of 6 h prior to 
imaging. Mice were injected with 500 mCi of 18F-FDG (ITP Cyclotron, Madrid) into the lateral tail vein. 
During imaging, mice were anesthetized with a continuous flow of 1% to 3% isoflurane (2 L/min). Forty-
five minutes after radiotracer injection, micro-CT images were collected: 400 projections were acquired 
in one full rotation of the gantry, in approximately 10 min. Again, the image acquisition was not 
respiratory-gated. The X-ray tube settings were 40 kV and 300 lA. Immediately after micro-CT, micro-
PET scans were acquired. CT images were reconstructed using filtered back projection with a Shepp–
Logan filter and PET images with 3D OSEM reconstruction algorithm. PET/CT images were analyzed 
using MMWS software (eXplore Vista, GEHC) for tumor FDG uptake. For PET quantification, tumor 
regions of interest (ROIs) were selected in the PET-CT overlapped image. In these ROIs, the 
standardized 18F-FDG uptake value (SUV) was calculated using the following formula:  
SUV = Tumor FDG Concentration (MBq) / (injected dose/Body weight)  
 
1.6. Allograft and xenograft experiments 
 
1.6.1. Downregulation of TRF1 in mouse and human lung cancer cell lines 
For allograft and xenograft experiments, three independent K-Ras∆/LG12Vgeo p53-/- mouse tumor-
derived cell lines (M. Barbacid’s gift) and the A549 human carcinoma cell line (ATCC nº; CCL-185) were 
infected with a shRNA against Trf1 (pLKO.1-puro-Trf1 shRNA, Sigma-Aldrich).  
 
1.6.2. Allograft and xenograft injections and tumor follow-up 
For allograft experiments 150 000 and 50 000 control and Trf1-dowregulated K-Ras∆/LG12Vgeo 
p53-/- mouse tumor-derived cells were intravenously or subcutaneously injected in athymic mice, 
respectively.  
For xenograft experiments, 150 000 control and Trf1-dowregulated human lung cancer cells 
were injected subcutaneously. Subcutaneously grown tumors were measured every other day. Three 
weeks after injection all mice were sacrificed. Lungs were fixed and included in paraffin for tumor area 
quantification. Subcutaneously grown tumors were measured, weighted and included in paraffin blocks. 
Tumor volume was determined by the following equation: V = (4/3) * (a/2)* (b/2) * (c/2) * Π, where a, b 
and c are tumor length, width and high, respectively.  
 
2. Sample collection and histological analysis 
All mice were sacrificed in CO2 chamber (except for embryos and newborns, that were 
sacrificed by decapitation). Upon mouse sacrifice, all tissues of interest were isolated, fixed 24h in 10% 
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buffered formalin (Sigma) and embedded in paraffin blocks. Histological analysis was done in 4 µm 
sections, with bright field microscopy in a blindly manner by a pathologist.  
For Trf1Δ/Δ K5Cre Chk2-/- mice, the deepest analysis was done in the stratified epithelia. For 
Terc-/- Chk2-/- mice, all organs were analyzed. For K-Ras+/G12V Trf1lox/lox p53-/- mice, 4/5 of lung lobes were 
fixed in 10% buffered formalin (Sigma) and embedded in paraffin. The remaining 1/5 of lung lobe was 
processed for whole-mount X-Gal staining to detect β-Geo, as a surrogate marker for K-RasG12V 
expression (Guerra et al, 2003) and then embedded in paraffin blocks. For quantification and 
classification of tumor lesions, the whole lung was serially sectioned and tumors were counted and 
analyzed by a pathologist. Following the classical histopathology criteria for the diagnosis of malignancy 
(local/vascular invasion and metastasis), the pathologist classified the tumors into adenomas (benign) 
and adenocarcinomas (malignant). Due to the high cellular atypia (anaplasia) observed in the Trf1∆/∆ K-
Ras+/G12V p53-/- tumors, pure lepidic growth lacking invasion, regardless of the cellular atypia was 
classified as benign. Three sections of each lung were digitally scanned (Mirax Panoramic Scanner, 
3DHistech) for tumor measure with Panoramic Viewer software. 
 
3. X-gal staining, immunohistochemistry and immunofluorescence 
 
3.1. Whole-mount X-gal staining 
1/5 of the lung was collected for X-gal staining in whole mount. The tissue was fixed during 
1h30 in fixative solution (0.2% glutaraldehyde, 1.5% formalin, 2 mM MgCl2, 5 mM EGTA, 100 mM 
sodium phosphate pH 7.3). The tissue was washed three times (20 each wash) with washing solution 
(0.2% NP-40, 0.01% sodium deoxycholate, 2mM MgCl2, 100mM sodium phosphate pH 7.3). The tissue 
was then incubated for 48h at 37ºC with the staining solution (0.2% NP-40, 0.01% sodium deoxycholate, 
2mM MgCl2, 100 mM sodium phosphate pH 7.3, 5mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 1 mg/mL X-Gal). 
Three washes of 20 min were then performed with the washing solution. The tissue was post-fixed over 
night in buffered 10% formalin and washed twice with PBS for 5 min. The tissue was dehydrated 1 hour 
in 50% ethanol and 1 hour in 70% ethanol. Finally, the Histopathology Unit of the CNIO embedded it in a 
paraffin block, perfomed 4 µm sections and counter-stained them with nuclear fast red. 
 
3.2. Immunohistochemistry 
Immunohistochemistry was performed at the Histopathology Unit of the CNIO, following 
standard procedures, on 4 µm sections. 
Briefly, sections were deparaffinized, rehydrated, and antigen retrieval was performed by 
cooking the sections in 10 mM citrate buffer under high pressure during 2 min. After blocking, sections 
were incubated with primary antibodies 16h at 4ºC, washed, incubated with biotin-conjugated secondary 
antibodies. Then, sections were processed for indirect peroxidase detection (Vector Laboratories) with 
DAB as a substrate (Dako). Finally, slides were counter-stained with hematoxilin-eosin and mounted.  
 
3.3. Immunofluorescence and microscopy 
Immunofluorescence was performed following standard procedures.  
In summary, sections were progressively re-hydrated in 90º-80º-70º ethanol (5 min in each) and 
then permeabilized 1h in PBS 0.3% Triton. Sections were blocked 1h30 in Australian FBS calf serum 
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and then incubated at 4ºC over night with the primary antibody diluted in a commercial antibody diluent 
with background-reducing components (Dako, S3022). Three PBS 0.1% Tween washes of 10 min each 
were performed, and sections were incubated 1h with the secondary antibody diluted in Dako diluent 
with background-reducing components. After three PBS 0.1% Tween washes, sections were put in a 
DAPI bath (4µg/ml DAPI, Sigma) and then mounted with Prolong anti-fade reagent.  
RAP1 & γH2AX double immunofluorescence and TRF1 inmunofluorescence images were 
obtained using a confocal multiphoton ultraspectral microscope (Leica TCS-SP5 MP). 
 
3.4. Antibodies 
Commercial antibodies used for immunostaining included those raised against: phospho-
histone H3 Ser 10 (06-570, Millipore), phospho-H2AX Ser 139 (05-636, Millipore), 53BP1 (Ab-36823, 
Abcam), p21 (sc-397, Santa Cruz Biotechnology), p53 (1C12, Cell Signalling), Ki67 (Master 
Diagnostico), cytokeratin 6 (Covance), RAP1 (BL735, Bethyl), TRF1 TRF-78 (ab10579, Abcam), and 
active Caspase 3 (AF835, R&D Systems). β-galactosidase and TRF1 home-made antibodies were both 
generated at CNIO Monoclonal Antibodies Unit, and kindly provided by G.Roncador. 
 
4. Cell culture assays 
 
4.1. Trf1/Chk2 MEFs  
Trf1/Chk2 MEFs (with no K5Cre sequence) were isolated from E13.5 embryos, expanded 
according to standard protocols, and were grown in DMEM supplemented with 10% fetal calf serum and 
antibiotics/ antimycotics. 1-3 × 106 MEFs were plated in p150 plates and grown. 2 days before infection, 
they were put in serum starvation conditions (DNEM with 0.1% calf serum). When confluence was 
reached, MEFs were infected with adenoCre (4 x 106 PFUs/plate, Iowa University -ILabsolutions) diluted 
in DNEM with 0.1% calf serum. After 48h of infection the medium was removed, new supplemented 
DNEM (with 10% fetal calf serum) was added and assays were started. Trf1 excision was monitored by 
PCR as previously described (section 1.3.2). For proliferation assays and β-galactosidase assay, one 
day after the end of the infection 5 x 104 MEFs were plated on six-well plates, with duplicates. Their 
growth rate was determined using an automatic cell counter (Millipore Scepter Automatic Cell Counter), 
on days 2, 3, 4 and 6 post-plating. β-galactosidase senescence-associated activity was detected using a 
commercial kit (Cell Signalling) on three time points (days 4; 6-7; 8-11 post-plating). 10000-30000 
infected MEFs were plated in round coverslips for posterior fixation and immuno-FISH. 
 
4.2. Trf1/K-Ras/p53 MEFs   
Trf1/K-Ras/p53 MEFs were obtained and expanded as previously described. 1-3 x 106 MEFs 
were plated and infected 3 times with pBabeCre viral supernatant supplemented with 4 µg/mL 
polybrene. MEFs were then selected with 2 µg/mL puromycin for 3 days. For all the assays performed, 
they were kept on DMEM with puromycin supplemented with 10% fetal calf serum. Trf1 excision was 
monitored by PCR as previously described in section 1.3.2.  
For proliferation assays, 5 x 104 cells were plated on six-well plates, with duplicates. Their 
growth rate was determined using an automatic cell counter (Millipore Scepter Automatic Cell Counter), 
on days 2, 3, 4, 5 and 7 post-plating.  
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For colony formation assays, 5000 cells were seeded on 10-cm plates, with duplicates. After 2 
weeks, cells were fixed and stained with GIEMSA. Colonies were counted and measured. β-
galactosidase senescence-associated activity on day 7 was detected using a commercial kit (Cell 
Signalling). 
 
5. Western blotting 
Western blot was performed on Trf1/Chk2 keratinocytes and on Trf1/K-Ras/p53 MEFs (day 7 
post-infection) following standard procedures. Briefly, total extraction of proteins was performed with 
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40) with freshly added protease inhibitors 
(PSMF and Sigma Protease Inhibitor Cocktail) and phosphatase inhibitors (Na3Vo4 and NaF). Protein 
quantification was performed by Bradford method (Sigma). For each sample, loading buffer was added 
1:4 to an amount of protein extract containing 30 µg. The resulting samples were loaded in a NuPAGE 
4-12% Bis-Tris polyacrylamide gel (Invitrogen). Gel running lasted 3h with a voltage of 120 V in MES 
SDS Running Buffer (Invitrogen). Protein transfer from the gel to a membrane was performed at RT 1h 
with 100V in transfer buffer. Transfer buffer was prepared with 1 part of transfer buffer 10x (0.1 M Tris-
HCl, 0.5 M NaCl 0.5% of Roche Blocking Reagent), 2 parts of methanol and 7 parts of H2O. Membrane 
blocking was done in TBS 0.1% Tween with 5% of non-fat milk. Membrane was incubated over night at 
4ºC with the primary antibody diluted 1:1000 in TBS 0.1% Tween with 5% of non-fat milk. 3 washes of 
10 min in TBS 0.1% Tween were performed and membrane was incubated with secondary antibody for 
1h at room temperature. 3 washes of 5 min each were performed in TBS 0.1% Tween. Protein was 
detected in a chemoluminescence-sensitive film (Amersham Hyperfilm ECL) exposed to the reagent-
treated membranes (Amersham ECL detection reagent).  
 The antibodies used for western blot were raised against P-CHK1 (Ser 345, Cell Signalling), 
total CHK1 (G-4, sc-8408, Santa Cruz Biotechnology), CHK2 (Millipore 05-649) and active Caspase 3 
(Asp 175, Cell Signalling). 
 
6. In situ hybridization 
 
6.1. Telomere measure by Quantitative Fluorescence In situ Hybridization (qFISH) 
qFISH was performed in Trf1/K-ras/p53 lung tumor sections and in Terc/Chk2 intestine sections 
as described previously (Samper et al, 2000). Briefly, after deparaffinization, tissues were post-fixed in 
4% Formaldehyde 5 min, washed 3x5min in PBS and incubated at 37ºC 15 min in pepsin solution (0.1% 
Porcine Pepsin, Sigma; 0.01M HCl, Merck). After another round of washes and fixation as above-
mentioned, slides were dehydrated in a 70% - 90% - 100% ethanol series (5 min each). After 15 min of 
air drying, 50µl of telomere probe mix (10mM TrisCl pH7, 25mM MgCl2, 9mM Citric Acid, 82 mM 
Na2HPO4, 70% Deionised Formamide -Sigma-, 0.25% Blocking Reagent -Roche- and 0.5µg/ml 
Telomeric PNA probe -Panagene) were added to each slide. After putting a cover slip on top of it, DNA 
was denatured by heating during 3 min at 85ºC, and further incubated for 2h at RT in a wet chamber in 
the dark. Finally, slides were washed 2x15 min in Washing Solution I (10 mM TrisCl pH7, 0.1% BSA in 
70% formamide), then 3x5 min in Washing Solution II (TBS 0.08% Tween) and then incubated with 
DAPI bath (4µg/ml DAPI, Sigma) and mounted in Vectashield mounting medium (VectorTM). 
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For tumor telomere length measure, 3 confocal image stacks were acquired every 0.5 µm for a 
total of 1.5 µm by using a Leica TCS-SP5 MP confocal microscope. Maximum projections were 
generated using LAS-AF software. Telomere length was quantified using Definiens software. For 
intestine telomere length analysis, images were recorded at room temperature using a camera (CCK; 
Cohu, Inc.) on a fluorescence microscope (DMRB; Leica) with a mercury vapor lamp source (CS 100 W-
2; Philips) with a 100× oil objective to get a 1,000 magnification. They were captured using Q-FISH 
software (Leica) in linear acquisition mode. TFL-Telo software (a gift from P. Lansdorp, BC Cancer 
Agency, Vancouver, British Columbia, Canada) was used to quantify fluorescence intensity of telomeres 
(Zijlmans et al, 1997). For both intestine and tumor samples, the images from the different genotypes 
analyzed were captured on the same day, in parallel, and blindly. 
 
6.2. Immuno-FISH 
Infected MEFs growing in round coverslips were fixed and subjected to immunofluorescence 
staining as described in 3.3, using anti-53BP1 (Ab-36823, Abcam). After washing, samples were fixed 
again in 4% formaldehyde in PBS, and telomeric FISH was performed as described in 6.1., reducing 
formamide concentration to 30%, and omitting pepsine digestion step.  
 
6.3. FISH and cytogenetic analyses on metaphase spreads 
Metaphases were prepared as previously described (Samper et al, 2000). To sum up, 
Terc/Chk2 and Trf1/Chk2 MEFs were grown for 4 hours at 37°C in DMEM containing 0.1 µg/ml 
colcemid. After that, cells were incubated with hypotonic solution (0.4% KCl, 0.4% Sodium citrate) and 
fixed with cold methanol/acetic acid (3:1). Then, cells were spread on slides and FISH was performed as 
described in 6.1. Images were recorded using a camera (CCK; Cohu, Inc.) on a fluorescence 
microscope (DMRB; Leica) with a mercury vapor lamp source (CS 100 W-2; Philips) with a 100× oil 
objective to get a 1000 magnification.  
Analysis of chromosomal aberrations was done by superimposing the Q-FISH telomere image 
on the DAPI image using Leica Q-FISH software. Cytogenetic analysis of metaphases was performed 
blindly. Metaphases were scored for chromosome aberrations: 
-end-to-end chromosome fusions: Robertsonian-like fusions (p:p arm fusions), dicentrics (q:q 
arm fusions) and p:q arm fusions;  
-rings (chromosomes with two fused chromatids without telomere signal at the fusion point) 
-chromatid fusions (fusions between chromosomes by one chromatid);  
-chromatid breaks (gaps in chromatids with an identifiable corresponding chromosome); 
-multi-telomeric signals (MTS), which are a read-out of regions of uncompleted DNA replication 
and/or stalled replication forks (Martinez et al, 2009b; Sfeir et al, 2009); 
-fragments (with two telomere signals or less, and without an identifiable corresponding 
chromosome).  
 
7. qPCR 
RNA extraction was performed following standard procedures, with RNeasy Mini Kit (Qiagen). 
During the extraction, samples were treated with DNase I (Qiagen). Reverse transcription was carried 
out using iScript cDNA Synthesis Kit (Bio-Rad), according to the manufacturer’s protocol. Quantitative 
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real-time PCR was performed using DNA Master SYBR Green mix (Applied Biosystems) and 7500 Fast 
Real-time PCR machine (Applied Biosystems) according to the manufacturer`s protocol.  
Trf1 expression was quantified by qPCR using the following primers:  
TRF1 FB (5’ TCT AAG GAT AGG CCA GAT GCC A 3’)  
TRF1 RB (5’CTG AAA TCT GAT GGA GCA CGT C 3’) 
Actin was used as a house keeping gene, using the following primers: 
ACT Fw (3’ GGC ACC ACA CCT TCT ACA ATG 5’) 
ACT Rv (3’ GTG GTG GTG AAG CTG TAG 5’) 
We determined the relative expression of Trf1 in each sample by calculating the 2∆CT value. 
For each sample, 2∆CT was normalized to the control 2∆CT mean. All values were obtained in 
triplicates. 
 
8. Statistical analysis 
The statistical analysis showed was performed with Graphpad Prism software. 
The following statistical tools were used, depending of the analysis:  
-for the comparison of one variable across genotypes (for example, the arbitrary fluorescent 
units of the different genotypes): T-Test or Chi-square test. 
-for the comparison of survival curves: Log-rank (Mantel-Cox) test 
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PART 1. Study of the role of CHK2 in signalling telomere 
dysfunction 
 
 
Telomere dysfunction elicits a DNA damage response that activates the ATM/ATR pathway, 
eventually leading to a p21/p53-dependent cell cycle arrest, senescence and/or apoptosis. CHK2 is a 
direct target of ATM in the DDR, and contributes to cell cycle arrest by two means. Firstly, CHK2 directly 
activates p53. Secondly, CHK2 inhibits Cdc25a, which is an activator of the cell cycle-dependent kinase 
CDK2 crucial to allow G1/S transition (Falck et al, 2001; Mailand et al, 2000). The role of CHK2 in 
signalling telomere dysfunction in vivo has not fully been addressed. 
We set to address the in vivo role of CHK2 in signalling telomere dysfunction either originated 
by telomere uncapping or by telomere shortening, to test whether Chk2 abrogation could ameliorate the 
proliferative defects and degenerative pathologies associated to telomere dysfunction. To that end, we 
crossed mice with whole-body Chk2 deletion, Chk2-/- (Hirao et al, 2002); with Trf1∆/∆ K5Cre mice 
(Martinez et al, 2009b). Chk2-deficient mice are viable and do not show increased cancer incidence 
(Barlow et al, 1996; Donehower et al, 1992; Hirao et al, 2002), constituting an interesting model to test 
the importance of this checkpoint kinase in mediating telomere dysfunction in vivo.  
 
 
1.1. CHK2 role in Trf1-mediated telomere uncapping 
 
1.1.1. Chk2 deficiency rescues mouse survival and degenerative pathologies in Trf1-deficient 
mice 
Chk2 deficiency significantly rescued the survival of Trf1∆/∆ K5Cre mice, with one doubly deficient 
mice surviving for as long as 1 year of age compared to a maximum survival of 4 days for single Trf1-
deficient littermates (Figure 10a). On average, the median survival of the Trf1∆/∆ K5Cre Chk2-/- mice was 
three-fold higher than the Trf1∆/∆ K5Cre mice, 0.9 and 0.3 weeks respectively (Figure 10a). In 
agreement with the increased survival, we also observed a significant rescue of body weight in Trf1∆/∆ 
K5Cre Chk2-/- newborns compared to the Trf1∆/∆ K5Cre newborns (Figure 10b-c).  
In an analogous manner, the frequency and severity of epithelial pathologies associated to Trf1 
deficiency such as hair follicle atrophy, skin interfollicular dysplasia and oesophagus dysplasia were also 
significantly rescued in Trf1∆/∆ K5Cre Chk2-/- newborns (1-2 day old mice) compared to the Trf1∆/∆ K5Cre 
Chk2+/+ age-matched controls (Figure 10d-e). Aberrant overexpression of cytokeratin 6 associated to 
Trf1 deficiency was also decreased in the Chk2-deficient background (Figure 10d-e). Interestingly, at 9 
days of age, at which point all single mutant Trf1∆/∆ K5Cre mice were dead, surviving Trf1∆/∆ K5Cre 
Chk2-/- mice showed extensive dysplasia in the skin, suggesting an increased pre-neoplastic growth 
associated to massive Trf1-induced DNA damage in the absence of Chk2 (Figure 10d). 
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Figure 10. Chk2 deficiency partially rescues Trf1∆/∆ K5Cre phenotypes and lethality (A) Survival curve of Trf1∆/∆ K5Cre Chk2-/- 
and Trf1∆/∆ K5Cre Chk2+/+ mice. Statistical analysis was done by the Log-rank (Mantel-Cox) test. **, p<0.01. (B) Weight at birth of 
the indicated genotypes. T-test was used for statistical analysis. *, p<0.05; **, p<0.01; ***, p<0.001. (C) Representative images of 
newborns and two week old mice of the indicated genotypes. (D) Percentage of newborns that show severe or moderate skin 
follicular atrophy, skin interfollicular dysplasia, oesophagus dysplasia, and strong CK6 expression. Severe follicular atrophy is 
characterized by a reduced number of hair follicle primordial that are completely undeveloped. Moderate follicular atrophy is 
characterized by a decreased differentiation degree as compared to wild-type. Interfollicular dysplasia is characterized by 
undifferentiated keratinocytes, cellular depolarization and hyperkeratosis.  Chi-square test was performed for statistical analysis. (E) 
Representative images of hematoxylin-eosin and cytokeratin 6 staining in newborn skin and oesophagus of the indicated genotypes. 
Dysplasic areas are marked with an asterisk and undeveloped hair follicles with an arrow.  
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1.1.2. Chk2 deficiency reduces p53 induction and increases proliferation of the skin of K5Cre 
Trf1∆/∆ Chk2-/- newborns 
To further investigate how Chk2 deficiency could rescue both the severity of the skin 
pathologies and survival of Trf1∆/∆ K5Cre Chk2-/- mice compared to Trf1∆/∆ K5Cre Chk2+/+ littermates, we 
first set to quantify DNA damage in the skin of these mice by determining the number of cells showing 
DNA damage foci as indicated by γH2Ax and 53BP1 double staining. γH2AX and 53BP1 are both ATM 
targets that accumulate at DSBs and at uncapped telomeres. Indeed, in response to DSB formation, 
ATM phosphorylates histone H2AX in Ser139 position, the phosphorylated form being called γH2AX 
(Bakkenist & Kastan, 2003; Helt et al, 2005; Kastan & Lim, 2000; Rogakou et al, 1998). γH2AX 
accumulates at DSB and serves as a platform for the anchoring of other repair factors like MRN complex 
or 53BP1 (Celeste et al, 2003; Paull et al, 2000; Stucki & Jackson, 2006). Both Trf1∆/∆ K5Cre Chk2+/+ 
and Trf1∆/∆ K5Cre Chk2-/- newborn skin showed approximately 80% of the basal cells positive for γH2AX 
and 53BP1 staining (> 5 foci per cell), indicating similarly high amounts of DNA damage in both cases, in 
agreement with similarly high levels of telomere uncapping owing to Trf1 deficiency (Figure 11a-b). In 
conditional Trf1-deleted MEFs by Cre-adenovirus infection we found also similar amounts of DNA 
damage (Figure 12c-e), as well as similar frequencies of chromosomal aberrations and senescence 
associated to Trf1 deficiency in in vitro grown MEFs deficient for both Trf1 and Chk2 (Figure 12d-e), 
thus confirming the in vivo findings.  
 
 
Figure 11. Similar amount of DNA damage in Trf1∆/∆ K5Cre Chk2+/+ and Trf1∆/∆ K5Cre Chk2-/- newborn skin and MEFs. (A) 
Representative images of γH2AX and 53BP1 double immunofluorescence performed on newborn skin. (B) Percentage of cells 
showing 5 or more γH2AX and 53BP1 damage foci. 1500-2000 cells were analyzed per genotype. (C) Representative image of 
53BP1 and telomeric PNA-probe immunoFISH performed on MEFs. Magnifications of foci are shown in the insets. Notice the co-
localization of telomere and the 53BP1 foci found in Trf1-deleted MEFs. (D) Percentage of MEFs with three or more 53BP1 and 
γH2AX foci. (E) Number of telomeric induced foci (TIFs) per MEF, determined by 53BP1 and telomeric-probe immunoFISH. T-test 
was performed for statistical analysis. *, p<0.05; **, p<0.01; ***, p<0.001. Error bars represent standard error. n=number of 
mice/MEFs analyzed per genotype. 
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In those MEFs, Trf1 deletion was confirmed by PCR (Figure 12a). Trf1-deficient MEFs showed 
CHK2 phosphorylation and decreased proliferation, as previously reported (Figure 12b-c) (Martinez et 
al, 2009b). Trf1∆/∆ Chk2-/- doubly-deficient MEFs showed the same proliferation defects than Trf1∆/∆ 
Chk2+/+ MEFs (Figure 12c).  
 
 
 
Figure 12. Chk2 deficiency does not rescue the Trf1-associated phenotypes in MEFs. (A) Trf1 deletion in MEFs upon Cre-
mediated infection was confirmed by PCR amplification of Trf1 locus. The different Trf1flox and Trf1∆ alleles are depicted. (B) 
Representative western blot images of phospho-CHK2 and CHK2 in the indicated genotypes. Actin was used as a loading control. 
(C) MEF growth curves of the indicated genotypes. (D) Percentage of senescent MEFs at days 4, 6-7, 8-11 post-infection, 
determined by β-galactosidase senescence-associated staining. (E) Percentage of multitelomeric signals, chromosomal and 
chromatid fusions per metaphase. Representative images of the chromosomal aberrations are shown. Error bars represent standard 
error. n=number of MEFs of each genotype. T-Test was performed for statistical analysis. *, p<0.05; **, p<0.01; ***, p<0.001.   
 
Interestingly, although the amount of DNA damage was similar independently of the Chk2 
status, we found a decreased induction of p21 and p53 in the epidermis of Trf1∆/∆ K5Cre Chk2-/- doubly 
deficient mice compared to that of single Trf1 knock-outs (Figure 13a-c). This was also paralleled by a 
higher proliferation in Trf1∆/∆ K5Cre Chk2-/- compared to Trf1∆/∆ K5Cre Chk2+/+ newborn epidermis as 
determined by Ki67-positive cells (Figure 13a,d). Of note, despite this rescue, p53 levels were still 
significantly higher in Trf1∆/∆ K5Cre Chk2-/- epidermis compared to wild-type (Figure 13a,c), which may 
be indicative of p53 activation through the alternative ATR/CHK1 pathway (d'Adda di Fagagna et al, 
2003; Jazayeri et al, 2006; Martinez et al, 2009b; Sfeir et al, 2009; Zou & Elledge, 2003). In this regard, 
we observed a 3-fold increase in p-CHK1 levels in Trf1∆/∆ K5Cre Chk2-/- compared to Trf1∆/∆ K5Cre 
keratinocytes (Figure 13e-f).  
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Figure 13. Chk2 deficiency reduces p21/p53 induction and increases proliferation of the skin of K5Cre Trf1∆/∆ Chk2-/- 
newborns. (A) Representative images of p21, p53 and Ki67 immunohistochemistries performed on newborn skin. (B-D) Percentage 
of p21-positive cells (B), p53-positive cells (C), and Ki67 positive cells (D) in the newborn basal skin layer of the indicated 
genotypes. 1500-2000 cells were analyzed per genotype. (F) Representative image and quantification by western blot of phospho-
CHK1 normalized to total CHK1 in newborn keratinocytes. T-test was performed for statistical analysis. *, p<0.05; **, p<0.01; ***, 
p<0.001. Error bars represent standard error. n represents the number of mice analyzed per genotype. 
 
 
 
1.1.3. Chk2 deficiency in Trf1∆/∆ K5Cre Chk2-/- mice leads to epithelial abnormalities characteristic 
of telomere syndromes, including increased skin cancer  
Interestingly, cell division in the presence of persistent DNA damage in long-lived Trf1∆/∆ K5Cre 
Chk2-/- mice resulted in development of epithelial pathologies, which recapitulate some of the skin 
abnormalities characteristic of the human telomere syndromes, such as occurrence of nail dystrophy 
and fibropapilomas (Figure 14a-b). In addition, the back skin displayed pre-neoplasic lesions such as 
epithelial hyperplasia and dysplasia, orthokeratotic hyperkeratosis, and dermal infiltrates. In addition, 
long-lived Trf1∆/∆ K5Cre Chk2-/- mice also showed spontaneous development of invasive squamous cell 
carcinomas (SCC) both in the tail and ear skin (Figure 14a-b). 
Altogether, these results demonstrate that Chk2 deletion attenuates induction of p53/p21 as 
well as rescues proliferative defects in the skin of Trf1∆/∆ K5Cre mice, which in turn leads to a partial 
rescue of survival but also to increased tumorigenesis. 
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Figure 14. Chk2 deficiency in Trf1∆/∆ K5Cre Chk2-/- mice leads to epithelial abnormalities characteristic of telomere 
syndromes, including increased skin cancer. (A,B) Representative images of the longer-lived TRF1∆/∆ K5Cre Chk2-/- mouse 
compared to a wild type littermate at different ages. Macroscopic lesions, fibropapiloma, nail dystrophy and squamous cell 
carcinoma in ear and tail skin are shown. 
 
 
1.2. CHK2 role in Terc-mediated telomere shortening 
 
1.2.1. Chk2 deficiency increases median survival of G1 and G2 Terc-deficient mice, ameliorates 
aging pathologies associated to Terc deficiency 
To address the effect of Chk2 deletion in a model of telomeric dysfunction originated by 
telomere shortening, we crossed Chk2-/- with telomerase deficient Terc-/- knock-out mice (Blasco et al, 
1997; Hirao et al, 2002; Takai et al, 2002). The Chk2+/- Terc+/- mice were further crossed to generate 
successive generations (G1-G3) of Chk2-/- Terc-/- mice, which progressively shorter telomeres. Similar to 
the results obtained in Trf1∆/∆ MEFS, critically short telomeres induced CHK2 phosphorylation, and 
Chk2-/- G1-G3 Terc-/- presented similar incidence of chromosomal aberrations and senescent cells as the 
Chk2+/+ G1-G3 Terc-/- MEFs (Figure 15a-c). 
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Figure 15. Similar incidence of chromosomal aberrations damage in Terc-/- Chk2+/+ and G2-G3 Terc-/- 
Chk2-/- MEFs (A) Representative western blot images of phospho-CHK2 and CHK2 in MEFs of the indicated 
genotypes. Tubulin was used as a loading control. (B) Percentage of multitelomeric signals, chromosomal 
and chromatid fusions per metaphase in MEFs of the indicated genotypes. Chi-square was performed for 
statistical analysis. (C) Percentage of senescent MEFs. T-test was performed for statistical analysis. Error 
bars represent standard error.  
 
 
Again, in vivo analysis of successive generations of these mice revealed that Chk2 deletion 
could significantly rescue survival of the first two generations (G1 and G2) of telomerase deficient-mice 
(Figure 16a). This rescue was not due to an effect of Chk2 deletion on telomere length, as we detected 
similar telomere shortening in successive of Chk2-/- G1-G3 Terc-/- and Chk2+/+ G1-G3 Terc-/- mice 
(Figure 16b). 
In line with the increased survival, Chk2-/- Terc-/- mice showed a reduced incidence of severe 
intestinal atrophy, a frequent cause of death in the Terc-deficient mice (Figure 16c). Furthermore, 
decreased body weight presented by Terc-/- mice at their time of death was rescued by Chk2 deficiency 
in the first generation G1 Terc-/- (Figure 16d). At the molecular level, we observed a significantly 
decreased expression of p21 and p53 in intestinal crypts of G1-G2 Chk2-/- Terc-/- mice compared to the 
Chk2+/+ G1-G2 Terc-/- controls (Figure 16e-f), in line with the findings with Chk2-/- Trf1-/- mice (Figure 
11a-b). Of note, p53/p21 levels were still significantly higher in G1-G2 Chk2-/- Terc-/- intestines compared 
to wild-type, which indicates alternative mechanisms for p53/p21 activation (d'Adda di Fagagna et al, 
2003; Jazayeri et al, 2006; Martinez et al, 2009b; Sfeir et al, 2009; Zou & Elledge, 2003). 
Results 
 
 66
 
Figure 16. Chk2 deficiency improves mouse survival, intestinal degenerative pathologies and body weight of G1-G2 Terc-
deficient mice (A) Survival curves of G1-G3 Terc/Chk2 mouse cohorts. Statistical analysis was done by the Log-rank (Mantel-Cox) 
test. ns: no significant; *, p<0.05; **; p<0.01. (B) Telomere length analysis by q-FISH in the intestine of G1-G3 Terc/Chk2 mouse 
cohorts. (C) Quantification of severe intestinal degenerative lesions in Terc+/+ and G1-G3 Terc-/- in Chk2-proficient and deficient 
background at death point. (D) Body weight of G1-G3 Terc/Chk2 mouse cohorts at death point. (E-F) Percentage of p21-positive (E) 
and p53-positive cells (F) in the intestinal crypts of the indicated G1-G2 Terc/Chk2 mouse cohorts. T-Test was performed for 
statistical analysis in B, D, E and F. Error bars represent standard error. *, p<0.05; **, p<0.01; ***, p<0.001. n=number of mice of 
each genotype. 
 
 
1.2.2 Chk2 deficiency partially abolishes the tumor suppressor effect of short telomeres 
Terc-deficiency has been previously shown to have a potent tumor suppressor effect with 
increasing mouse generations (Gonzalez-Suarez et al, 2000; Greenberg et al, 1998; Lee et al, 1998; 
Rudolph et al, 1999).  In this regard, we found that, Chk2 deletion lead to a slightly increased tumor 
incidence compared to the single Terc-deficient cohorts (Figure 17a), suggesting that Chk2 deficiency 
could partially abolish the tumor suppressor effect of Terc deficiency.  
 
Figure 17. Chk2 deficiency abolishes the 
tumor suppressor effect of short telomeres. 
Percentage of mice that presented malignant 
tumors amongst G1-G3 Terc/Chk2 cohorts at 
death point. Chi-square was  performed for 
statistical analysis. 
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PART 2. Targeting TRF1 as an anti-cancer therapy in a lung 
cancer mouse model 
 
The activation of oncogenes enhance the activity of G1 and S cyclin-dependent kinases, 
generating a state in which the cell is forced to go through successive cell cycles without pausing 
(Hartwell & Kastan, 1994; Ortega et al, 2002). This pressure on DNA replication machinery and the 
replication defects that arise from it -as stalled replication forks with unprotected ssDNA- are known as 
“replicative stress”. The replication defects induced by oncogene replicative pressure can result in 
incomplete replication and chromosome breaks during the successive mitoses, thus generating an 
increasing amount of DNA damage and genetic instability (Di Micco et al, 2006; Gorgoulis et al, 2005).  
TRF1 has an essential role of for telomere replication (Martinez et al, 2009b; Sfeir et al, 2009). 
We hypothesized that the combined effect of oncogenic stress forcing cell cycle progression, associated 
to the strong replicative defects and telomere uncapping generated by TRF1 depletion could result in 
tumor cell death, thereby constituting a potential target for cancer therapy.  
 
2.1. The Trf1Δ/Δ K-rasG12V p53-/- lung cancer mouse model 
To assess the effect of Trf1 abrogation in the context of lung cancer induced by expression of 
the K-RasG12V oncogene, we crossed lox-stop-lox-K-RasG12V mice (Guerra et al, 2003) to a strain 
carrying a floxeable allele of Trf1 (Trf1lox/lox) either wild-type or deficient for p53 (p53-/-) (Martinez et al, 
2009b) (Figure 18). Lox-stop-lox-K-RasG12V construct (called from now and on K-RasG12V) carries an 
IRES-geo cassette knocked in within its 3’ non-translated sequences (Guerra et al, 2003). Geo is a 
bacterial gene that contains sequences from LacZ (the gene encoding the β-galactosidase) and neoR 
(the gene that confers resistance to neomycin) (Mountford et al, 1994). The internal ribosomal entry site 
(IRES) sequences placed 5’ of Geo allow bicistronic expression of the chimeric Geo protein and the K-
RASG12V oncoprotein upon Cre-dependent cleavage of the floxed STOP transcriptional cassette (Guerra 
et al, 2003). This strategy allows identification of K-RASG12V-expressing cells by staining for β-
galactosidase activity provided by the Geo protein. 
Cre recombinase expression allows simultaneous deletion of Trf1 exon 1 and excision of the K-
RasG12V STOP cassette, activating the expression of oncogenic K-RASG12V that leads to lung 
tumorigenesis (Figure 18) (Guerra et al, 2003). Given that the K-RasG12V oncogenic allele is in 
heterozygosis, we will designate it from now and on K-Ras+/G12V.  
 
 
Figure 18. Genetic model. Trf1lox and K-Ras LSLG12V alleles are depicted before and after Cre-mediated excision.  
K-Ras LSLG12V allele carries a mutation in codon 12 that generates a Glycine to Valine transition (V12).  
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2.2. Trf1 deficiency impairs the proliferation of MEFs expressing the K-RasG12V oncogene 
Primary mouse embryonic fibroblasts (MEFs) were transduced with a retrovirus encoding the 
Cre recombinase (pBabe-Cre). Deficiency in p53 was included as part of the experimental strategy to 
allow for the growth of Trf1-deleted cells, which otherwise show severe proliferative defects (Figure 19), 
as previously reported (Martinez et al, 2009b; Thanasoula et al, 2010). Interestingly, while Trf1+/+ K-
Ras+/G12V p53-/- MEFs showed a 16-fold increase in cell number at day 7 post plating, Trf1∆/∆ K-Ras+/G12V 
p53-/- MEFs only increased their population by 4-fold in the same period of time (Figure  19), indicating a 
severe growth impairment in the Trf1∆/∆ K-Ras+/G12V p53-/- cells compared to their Trf1+/+ K-Ras+/G12V p53-/- 
controls. 
 
Figure 19. Trf1 deficiency impairs cell 
proliferation of K-Ras+/G12V p53-/- MEFs. 
MEFs growth curve of the indicated 
genotypes.  
 
 
2.3. Trf1 deficiency induces senescence in K-RasG12V MEFs 
To address how Trf1 ablation impairs the growth of K-RasG12V-expressing MEFs, we first 
analyzed cellular senescence as determined by the β-galactosidase senescence-associated activity. β-
galatosidase activity is one of the best characterized markers for quantification of cellular senescence 
(Dimri et al, 1995; Itahana et al, 2007). This method relies on the fact that mammalian senescent cells 
present a β-galactosidase activity that is detectable at pH 6.0. This senescent enzymatic activity can be 
distinguished from the reporter β-galactosidase activity of our K-RasG12V mouse model, that works at a 
pH of 7.3.  
 Trf1∆/∆ K-Ras+/G12V p53+/+ MEFs presented 1.9-fold higher percentage of senescent cells at day 
7 post plating compared to Trf1+/+ K-Ras+/G12V p53+/+ MEFs (Figure 20a). Interestingly, p53 deficiency did 
not abolish Trf1 deficiency-mediated senescence. Indeed, Trf1∆/∆ K-Ras+/G12V p53-/- MEFs showed a 21-
fold higher percentage of senescent cells compared to Trf1+/+ K-Ras+/G12V p53-/- MEFs at day 7 post 
plating (Figure 20a). This increase in senescence is likely due to the additive effect of K-ras oncogene-
induced senescence and Trf1 deficiency-induced senescence (Martinez et al, 2009b; Serrano et al, 
1997). No significant differences in apoptosis were detected between genotypes as measured by 
caspase 3 activation (Figure 20b). Together, these results indicate that Trf1 abrogation in MEFs 
expressing mutant K-Ras leads to higher numbers of senescent cells even in the absence of p53. 
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Figure 20. Trf1 deficiency induces senescence in K-RasG12V MEFs. (A) Percentage of senescent MEFs at day 7 post plating 
determined by β-galactosidase senescence-associated staining. Error bars represent standard error. T-test was used for statistical 
analysis. *, p=0.05. (B) Caspase 3 activation quantified by western blot in MEFs of the indicated genotypes. Excised activated 
caspase 3 appears as a double band of 17 and 19 kDa.  
 
 
2.4. Trf1 deficiency impairs immortalization of MEFs expressing the K-RasG12V oncogene 
Next, we addressed the effect of Trf1 abrogation in immortalization of MEFs. To this end, we 
performed a colony formation assay (Materials and Methods), which reflects the clonogenic capacity of 
individual cells (Harvey et al, 1993; Jones et al, 1996; Kamijo et al, 1997). In this assay, cells are seeded 
at a low density. Under these conditions, only cells which are able to escape senescence will divide 
enough times to form visible colonies.  p53-proficient MEFs did not form any colonies in agreement with 
the fact that p53 wild-type MEFs do not spontaneously immortalize (Figure 21a-b) (Harvey & Levine, 
1991; Parrinello et al, 2003). In contrast, p53-deficient MEFs were able to form immortalized colonies, 
although Trf1∆/∆ K-Ras+/G12V p53-/- MEFs formed fewer and smaller colonies than Trf1+/+ K-Ras+/G12V p53-/- 
MEFs. These results indicate that Trf1 deficiency limits both proliferation and cellular immortalization of 
K-Ras-expressing cells in vitro even in the absence of p53. 
 
 
Figure 21. Trf1 deficiency impairs immortalization of MEFs expressing the K-RasG12V oncogene. (A) Colony formation assay 
performed in MEFs of the indicated genotype. Number and size of the colonies are represented. (B) Representative image of the 
colony formation assay. n= number of independent MEFs used per genotype. Error bars represent standard error. T-test was used 
for statistical analysis. *, p=0.05 
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2.5. Mice inoculation and follow-up by in vivo imaging 
Given the negative impact of Trf1 deletion in the in vitro growth and immortalization ability of 
MEFs expressing mutant K-Ras, we next set to determine the impact of Trf1 deficiency in vivo in the K-
Ras-induced lung carcinogenesis model. To this end, eight week-old Trf1lox/lox K-Ras+/G12V p53+/+ and 
Trf1lox/lox K-Ras+/G12V p53-/- mice, as well as their respective Trf1 wild-type controls, were infected by 
intratracheal instillation with replication-defective adenoviruses encoding the Cre recombinase (Adeno-
Cre) (Materials and Methods). This strategy allowed the expression of the resident K-RASG12V 
oncoprotein simultaneously with the ablation of the Trf1lox allele in the infected lung cells (Figure 18). 
Nine weeks after viral inoculation, a longitudinal follow up study of tumor growth was conducted by using 
computed tomography (CT) every second week until week 24th post-infection at which point the 
experiment was concluded. At 22 weeks post-infection, positron emission tomography (PET) was 
performed to monitor tumor malignancy (Figure 22a). At 24th week post infection, the animals were 
sacrificed to carry a full histopathological analysis of the lungs, as well as to confirm K-RasG12V 
expression and Trf1 deletion in the lesions (Figure 22a). Trf1 deletion was monitored in all tumors by 
TRF1 immunofluorescence and by PCR (Figure 22b-c). K-RasG12V expression in tumors was confirmed 
by detecting the expression of its beta-galactosidase (β-geo) reporter (Figure 22d). 
 
 
Figure 22. Efficient oncogenic K-RasG12V expression and Trf1 depletion in lung lesions. (A) In vivo imaging schedule. Eight-
ten week old mice were intratracheally infected with adeno-Cre, mice were analyzed every 2 weeks by computerized tomography 
(CT) and 22-weeks post infection a positron emission tomography (PET) was performed. Mice were sacrificed 24 weeks post-
infection for further histological analysis. (B) TRF1 immunofluorescence of the lungs. In Trf1lox/lox lungs, notice the absence of TRF1 
signal in the carcinomas and the presence of TRF1 signal in the surrounding healthy tissue. (C) Analysis of Trf1 excision by PCR. 
Notice the almost complete excision in the carcinomas of Trf1lox/lox lungs. (D) Detection of β-galactosidase activity in the lungs (by 
immonhistochemistry and X-gal staining), as a surrogate marker of oncogenic K-RasG12V expression.  
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2.6. Trf1 deficiency inhibits K-RasG12V-mediated lung cancer development, in a p53-proficient 
genetic background 
In vivo tumor follow-up by CT scan showed that, in a p53-proficient background, Trf1-deleted 
mice showed a delayed onset of time of appearance of the first CT scan-detectable lesions from 9 
weeks in the case of Trf1 wild-type lungs to 12 weeks in the case of the Trf1-deleted ones (Figure 23a). 
However, after this initial lag, both genotypes showed a similar growth of the tumor lesions according to 
CT scans (Figure 23a). Post-mortem lung analysis revealed that Trf1 wild-type and Trf1-deleted tumors 
were histologically identical. Importantly, immunofluorescence analysis of Trf1 expression in these 
lesions, showed that all tumors present in Trf1-deleted lungs were escapers and had normal Trf1 
expression (Figure 23b). These findings indicate that Trf1 is essential for K-RasG12V-induced lung tumor 
development in a p53-proficient background as no tumors lacking Trf1 expression were found (Figure 
23b).  
 
Figure 23. Trf1 deficiency inhibits K-RasG12V-mediated lung cancer development, in a p53-proficient genetic background. 
(A) Tumor growth curve of Trf1+/+ K-Ras+/G12V p53+/+ and Trf1∆/∆ K-Ras+/G12V p53+/+ measured by computed tomography (CT). Error 
bars represent standard error. n=number of mice analyzed per genotype. (B) Percentage of tumors that have deleted Trf1 quantified 
by TRF1 immunofluorescence after mice sacrifice. Post-mortem analysis of Trf1 deletion in each tumor revealed that none of the 
Trf1lox/lox K-Ras+/G12V p53+/+ ones had excised Trf1. 
 
 
2.7. Trf1 deficiency impairs K-RasG12V-mediated lung cancer growth and progression, and 
increases mouse survival, in a p53-deficient genetic background 
Next, we studied the impact of Trf1 deletion in K-RasG12V induced lung tumors in a p53-deficient 
background, a situation which resembles a large proportion of human lung tumors. In this case, in vivo 
CT and post-mortem histological analysis revealed that Trf1∆/∆ K-Ras+/G12V p53-/- tumors grew markedly 
slower and reached a smaller size at their end point than Trf1+/+ K-Ras+/G12V p53-/- tumors (Figure 24a-
b).  
To evaluate the malignancy of the lesions observed by CT, PET analysis was performed at 22 
weeks post-infection. The amount of circulating FDG-glucose uptaken by the tumor can be correlated 
with the metabolic activity and malignancy of this tumor (Moon et al, 2013; Valk et al, 1988). PET 
analysis at 22 weeks post-infection revealed that Trf1∆/∆ K-Ras+/G12V p53-/- tumors showed less metabolic 
activity than Trf1+/+ K-Ras+/G12V p53-/- tumors indicating a lower grade of malignancy (Figure 24c-d). 
Notably, in agreement with the lower malignancy, Trf1lox/lox K-Ras+/G12V p53-/- mouse survival was 
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significantly higher than that of Trf1+/+ K-Ras+/G12V p53-/- mice (Figure 24e). Of note, in this setting only 
5% of the Trf1lox/lox p53-/- tumors were found to be escapers (Figure 23b). 
 
 
Figure 24. Trf1 deficiency impairs K-RasG12V-mediated lung cancer growth and progression, and increases mouse survival, 
in a p53-deficient genetic background. (A) Tumor growth curve of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- 
measured by CT, that only detects tumors above 1 mm of section. Error bars represent standard error. (B) Tumor maximal section 
of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- lungs measured post-mortem on the digitally-scanned lung sections, that 
allowed the measure of every tumor independently of its size. Error bars represent standard error. (C) Maximum 18F-FDG-glucose 
uptake by Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- tumors 22 weeks after infection by positron emission tomography 
(PET). Error bars represent standard error. T-Test was used for statistical significance, **, p<0.01. The number of lesions and mice 
analyzed per genotype is indicated. (D) Representative PET-CT image of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- 
lungs. (E) Survival curve of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- mice. Log-rank (Mantel-Cox) test was used, *, 
p=0.05. n=number of mice analyzed per genotype. 
 
 
Upon mouse sacrifice, we performed a full histopathological analysis of the lungs and classified 
the lesions in benign adenoma lesions or malignant adenocarcinoma lesions (Figure 25a-b). First, blind 
histopathological analysis of the lesions confirmed that Trf1∆/∆ K-Ras+/G12V p53-/- lungs developed lower 
number of carcinomas than Trf1+/+ K-Ras+/G12V p53-/- lungs (Figure 25a-c). In addition, we found a 
smaller size of the malignant lesions in Trf1∆/∆ K-Ras+/G12V p53-/- lungs compared to Trf1+/+ K-Ras+/G12V 
p53-/- lungs (Figure 25a-c). Interestingly, Trf1∆/∆ K-Ras+/G12V p53-/- lungs presented a higher number of 
benign adenoma lesions than Trf1+/+ K-Ras+/G12V p53-/- lungs (Figure 25d). These findings suggest that 
although Trf1 deletion may favor tumor initiation by promoting the appearance of benign adenoma 
lesions, it dramatically impairs progression of these benign lesions to full-blown carcinomas. A similar 
scenario has been previously described in the case of telomere dysfunction associated to presence of 
very short/uncapped telomeres after several generations of mice with telomerase deficiency (Begus-
Nahrmann et al, 2012; Farazi et al, 2003; Rudolph et al, 2001). 
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Figure 25. Trf1 deficiency impairs K-Ras–mediated lung cancer progression. (A-B) Representative images of Trf1+/+ K-
Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- lungs at death point. Arrow heads mark carcinomas (C) Quantification of the number 
and size of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas at death point. (D) Quantification of the number and 
size of Trf1+/+ K-Ras+/G12V p53-/- and Trf1∆/∆ K-Ras+/G12V p53-/- adenomas at death point. *, p=0.05; **, p<0.01, ns, non significant. 
 
 
2.8. Lung carcinomas deficient for Trf1 show increased telomeric DNA damage and increased 
apoptotic rates 
Previous reports have shown that abrogation of Trf1 in different cell types, including MEFs, 
epidermal cells, intestinal cells, and bone marrow cells, causes a persistent DNA damage response  at 
chromosome ends which leads to decreased cell viability (Beier et al, 2012; Martinez et al, 2010; 
Schneider et al, 2013; Sfeir et al, 2009). To address whether the decreased growth and lower 
malignancy of Trf1-deficient lung tumors was associated with increased DNA damage in the lesions, we 
determined the presence of γH2AX DNA damage foci and their co-localization to telomeres, the so-
called Telomere Induced Foci (TIFs) directly in sections from lung carcinomas. The percentage of 
γH2AX-positive cells was significantly higher in Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas compared to Trf1+/+ 
K-Ras+/G12V p53-/- carcinomas (Figure 26a). Furthermore, co-immunofluorescence staining of γH2AX foci 
with RAP1, a telomere-associated protein used here to localize telomeres, showed increased number of 
DNA damage foci at telomeres in Trf1∆/∆ K-Ras+/G12V p53-/- than in Trf1+/+ K-Ras+/G12V p53-/- carcinomas 
(Figure 26b). 
Trf1 deficiency-induced telomere DNA damage can have differential cellular outcomes 
depending on the cell type. While in cells of the intestinal epithelium Trf1 deletion leads to apoptosis 
(Schneider et al, 2013), in MEFs and bone marrow cells Trf1 deletion leads to senescence (Beier et al, 
2012; Martinez et al, 2009b). To address the cellular effects of increased telomere damage in lung 
carcinomas, we first determined the percentage of apoptotic cells present in the lung carcinoma lesions. 
The percentage of carcinoma cells that were positive for the apoptotic marker active caspase 3 (AC3) 
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was higher in Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas compared to Trf1+/+ K-Ras+/G12V p53-/- carcinomas 
(Figure 26c). Together, these findings indicate that Trf1 deletion in lung carcinomas leads to increased 
telomeric damage and subsequent induction of apoptosis. 
 
 
Figure 26. Trf1-deficient carcinomas present high amount of telomeric DNA damage and apoptosis. (A) Percentage of cells 
showing γH2AX foci in carcinomas of the indicated genotypes (left panel). Representative images of γH2AX immunohistochemistry 
(right panel). (B) Percentage of cells showing 3 or more γH2AX and RAP1 colocalizing foci (TIFs). Representative images of γH2AX 
and RAP1 double immunofluorescence (right panel). TIFs are indicated with red arrow heads. (C) Percentage of active caspase 3 
(AC3) positive cells. Representative images of AC3 immunohistochemistry (right panel). Error bars represent standard error. The 
number of mice and carcinomas analyzed per genotype is indicated. T-test was used. *, p=0.05; **, p<0.01; ***, p<0.001. 
 
 
2.9. Trf1 deficiency leads to lower proliferation, G2-arrest, and mitotic defects 
Trf1 deficiency leads to severe proliferative defects in several cell types where it has been 
studied (Beier et al, 2012; Martinez et al, 2009b; Schneider et al, 2013; Sfeir et al, 2009). To determine 
whether Trf1 deletion in the context of K-RasG12V-induced lung cancer also leads to proliferation defects, 
we performed Ki67 immunohistochemistry directly on lung carcinoma sections (Materials and Methods). 
In agreement with the smaller size of Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas, we observed a lower 
proliferation index (Ki67-positive cells) in Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas compared to Trf1+/+ K-
Ras+/G12V p53-/- carcinomas (Figure 27a). Next, to determine the cell cycle phase where Trf1-deleted 
cells showed defects, we analyzed the staining pattern of phospho-Histone H3 (Ser10). Mitotic 
phosphorylation of H3 initiates non-randomly at pericentromeric heterochromatin in late G2 interphase 
cells where staining is visualized as discrete foci. Following initiation, H3 phosphorylation spreads 
throughout the condensing chromatin and the staining increases progressively until complete nuclear 
staining of the mitotic chromatin is achieved (Hendzel et al, 1991). Thus, pH3 pan-nuclear staining is a 
distinctive feature of mitotic cells whereas pH3 foci pattern is characteristic of G2 cells. We found that 
the percentage of cells positive for G2-distinctive pH3 foci pattern was significantly increased in Trf1∆/∆ 
K-Ras+/G12V p53-/- carcinoma lesions compared to Trf1+/+ K-Ras+/G12V p53-/- lesions (Figure  27b), 
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suggesting that TRF1 depletion leads to a higher amount of G2-arrested cells in the tumors. In addition, 
analysis of PCNA positive cells, a marker of S-phase (Bauer & Burgers, 1990; Jaskulski et al, 1988; 
Waseem et al, 1992) revealed that the amount of PCNA-positive replicating cells was higher in the 
Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas (Figure  27c), suggesting that Trf1∆/∆ K-Ras+/G12V p53-/- cells are 
defective in completing replication, as previously reported for  Trf1∆/∆ cells (d'Alcontres et al, 2014; 
Martinez et al, 2009b; Sfeir et al, 2009).  
Persistent telomere damage in cells deficient for the mouse shelterin Pot1 proteins has been 
previously proposed to result in bypass of mitosis leading to endoreduplication and tetraploidy (Davoli et 
al, 2010). In line with this notion, Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas presented an increased number of 
giant nuclei indicative of endoreduplication, as well as increased anaphase bridges, compared to Trf1+/+ 
K-Ras+/G12V p53-/- carcinomas (Figure 27d-f). Similarly, Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas presented 
cells showing bizarre multilobulated nuclei and multipolar mitosis, which were not present in Trf1+/+ K-
Ras+/G12V p53-/- carcinomas (Figure 27f). This type of aberrant nuclei have been previously related to 
mitotic catastrophes (Vakifahmetoglu et al, 2008). Together, these observations indicate that lung 
carcinoma cells require TRF1 for proper completion of mitosis, and that Trf1 deletion in these cells leads 
to severe mitotic defects, similar to those produced by known mitotic poisons (Dumontet & Jordan, 2010; 
Jordan & Wilson, 2004; Manchado et al, 2012).  
 
 
Figure 27. Trf1 deficiency leads to G2-arrest and mitotic defects. (A) Percentage of Ki67 positive cells in the carcinomas of the 
indicated genotypes (left panel). Representative images of Ki67 immunohistochemistry (right panel). (B) Percentage of pH3 positive 
cells in the carcinomas of the indicated genotypes (left panel). Representative images of pH3 immunohistochemistry (right panel). 
(C) Percentage of PCNA positive cells in the carcinomas of the indicated genotypes. (D) Percentage of giant nuclei in the 
carcinomas of the indicated genotype. (E) Percentage of anaphase bridges out of total anaphases in the carcinomas of the indicated 
genotypes. (F) Representative images of giant nuclei, multilobulated nuclei, anaphase bridges and multipolar mitoses. Error bars 
represent standard error. The number of mice and carcinomas analyzed per genotype is indicated. T-test was used. *, p=0.05; **, 
p<0.01; ***, p<0.001. 
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2.10. Trf1-deficient lung carcinomas have normal telomere length 
To demonstrate that the increased apoptosis and proliferation defects observed in Trf1-deleted 
lung carcinomas were not associated to telomere shortening induced by Trf1 deficiency, we determined 
telomere length by telomere quantitative FISH directly performed on lung carcinoma sections. Indeed, 
we found that telomeres were longer in the Trf1∆/∆ K-Ras+/G12V p53-/- carcinomas compared to Trf1+/+ K-
Ras+/G12V p53-/- carcinomas (Figure 28a-c). As telomere length reflects the proliferative history of a given 
tissue, the observation that Trf1+/+ K-Ras+/G12V p53-/- carcinomas present shorter telomeres than TRF1-
deficient ones is likely to reflect the lower proliferation rate of Trf1-deficient tumors. 
 
Figure 28. Trf1-deficient carcinomas show a shorter proliferative history than wild-types. (A) Telomere length in the healthy 
pulmonary tissue of the indicated genotypes quantified by Q-FISH analysis. The number of mice per genotype is indicated in each 
case. (B) Telomere length in the carcinomas of the indicated genotypes quantified by Q-FISH analysis. The number of mice and 
carcinomas analyzed per genotype is indicated in each case. (C) Percentage of decrease in telomere length from healthy tissue to 
carcinomas, based on the Q-FISH data. Error bars represent standard error. The number of mice and carcinomas analyzed per 
genotype is indicated in each case. T-test was used. *, p=0.05; **, p<0.01. 
 
 
2.11. TRF1 downregulation in mouse and human cell lines derived from mutated K-Ras lung 
carcinomas impairs cancer growth and metastasis in allograft and xenograft models 
To validate these results using an independent strategy to inhibit TRF1, as well as to assess the 
effect of Trf1 abrogation in already established K-Ras induced lung tumors, we downregulated Trf1 
expression by using shRNA technology in three K-Ras∆/G12V p53-/- mouse cancer cell lines derived from 
three independent mouse lung carcinoma lesions kindly provided by M.Barbacid’s lab (Ambroglio et al., 
submitted), and assessed the effects on tumor growth using two independent allograft experiments. 
First, to address the effect of TRF1 inhibition in tumor growth in vivo, we subcutaneously injected 50 000 
lung carcinoma cells into immunodeficient mice and followed tumor onset and growth. TRF1 
downregulation resulted in a marked delay in tumor onset as well as in a significantly decreased tumor 
growth (Figure 29a-d). Three weeks after injection, mice were sacrificed and the tumors were 
histologically analyzed. We confirmed that TRF1 downregulation was maintained during in vivo tumor 
development (Figure 29e). TRF1-dowregulated tumors showed decreased proliferation and increased 
DNA damage as well as increased apoptosis compared to controls (Figure 29f-h). Again, in agreement 
with a role of TRF1 in telomere capping and chromosomal stability, TRF1-downregulated tumors 
presented a high proportion of aberrant nuclei and anaphase bridges (Figure 29i). 
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Figure 29. TRF1 downregulation in K-RasG12V transformed lung cells leads to a decreased tumor growth upon 
subcutaneous injection in athymic mice. The latency (A), volume (B) and weight (C) of subcutaneous tumors generated by 
control and TRF1-downregulated K-RasG12V transformed lung cells in athymic mice. (D) Representative images of the subcutaneous 
tumors. (E) TRF1 expression levels measured by qPCR in the injected cell line and in the subcutaneous tumors generated. (F-H) 
Number of Ki67-positive (F), number of γH2AX- positive (G) and number of active caspase 3-positive (H) cells per field in the 
subcutaneous tumors. (I) Representative images of aberrant giant nuclei and anaphase bridges in the TRF1-downregulated 
subcutaneous tumors compared to the normal nuclei of control tumors.  
 
 
Next, to study the effect of TRF1 inhibition in the metastatic potential of established lung cancer 
cells induced by K-Ras expression, we intravenously injected 150 000 K-Ras∆/G12V p53-/- lung cells into 
immunodeficient mice. Tail vein injection of tumor cells results in lung metastasis (Elkin & Vlodavsky, 
2001). Three weeks after injection, the mice were sacrificed and lungs were subjected to full 
histopathology analysis. We confirmed that TRF1 downregulation was maintained in the generated lung 
tumors (Figure 30a). Importantly, TRF1 downregulation resulted in smaller lung metastasis as indicated 
by decreased tumor area (Figure 30b-c). In addition, the lung metastasis with downregulated TRF1 
showed increased DNA damage, which was concomitant with decreased proliferation and increased 
apoptosis compared to controls (Figure 30d-f).  
These results indicate that even a partial decrease in TRF1 levels of approximately 50% in 
tumors very significantly impairs lung tumor growth and lung metastasis, thus supporting the notion that 
a therapy based on pharmacological downregulation of TRF1 could be effective.  
Next, we set to validate whether TRF1 depletion had similar effects on human lung cancer cell 
lines. To this end, we successfully downregulated TRF1 levels by using shRNAs in a K-ras-mutated 
human lung carcinoma cell line, the A549 (ATCC nº; CCL-185) (Figure 30g). We then injected 
subcutaneously in immunodeficient mice 150 000 cells either infected with sh-scrambled or Trf1-shRNA 
and followed tumor development. TRF1 downregulation resulted in a markedly delayed tumor onset and 
growth. Indeed, control cells started to develop tumors 11 days after injection while the latency of TRF1-
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depleted cells was of 17 days. Moreover, after 26 days of follow-up only two out of eight injections with 
TRF1-downregulated cells were able to generate tumors whose growth were significantly impaired as 
compared to control cells (Figure 7h). This result indicates that TRF1 downregulation blocks the growth 
of cell lines derived from already formed lung tumors both in mice and humans. 
 
Figure 30. TRF1 downregulation in K-RasG12V transformed lung cells leads to a decreased tumor growth and decreased 
metastatic potential upon intravenous injection in athymic mice. (A) TRF1 Immunofluorescence shows the downregulation of 
TRF1 in lung tumors of the mice intravenously injected with control and TRF1-downregulated cells. (B) Tumor area measured in the 
lungs of the mice intravenously injected with control and TRF1-downregulated cells. (C) Representative images of the lungs 
colonized by control and TRF1-downregulated cells, respectively. (D-F) Number of Ki67-positive (D), number of γH2AX-positive (E) 
and number of active caspase 3- positive (F) cells per field in the lung tumors. (G) TRF1 expression levels measured by qPCR in 
A549 cell line infected either with sh-scrambled or sh-TRF1. (H) Latency and growth of A549-derived tumors. Error bars represent 
standard error. The number of tumors analyzed per condition is indicated. T-test was used. *, p=0.05; **, p<0.01; ***, p<0.001.  
 
 
2.12. Transient whole-body Trf1 deficiency allows survival and normal tissue function 
A prerequisite that must be fullfilled by any potential anti-cancer target is that its systemic 
inhibition in healthy tissues does not compromise organism viability. To validate TRF1 as a bonafide 
drug target in lung cancer treatment, we set to analyze the effects of whole-body TRF1 depletion in the 
context of adult mice and its impact on long-term mouse viability. To this end, we first generated a 
Trf1lox/lox hUBC-CreERT2 mouse model in which the expression of CreERT2 is transcriptionally 
controlled by the ubiquitously and constitutively regulated ubiquitin promoter (Martinez et al, 2009b; 
Ruzankina et al, 2007) (Figure 31). 
 
Figure 31. Trf1lox/lox hUBC-CreERT2 genetic mouse model. 
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Then, twelve-week old Trf1+/+ hUBC-CreERT2 and Trf1lox/lox hUBC-CreERT2 mice were 
subjected to a tamoxifen-containing diet for seven weeks in order to induce Trf1 deletion. After this 
period of time, four mice of each genotype were sacrificed to analyze the extent of Trf1 deletion in a 
panel of different tissues as well as to perform full histopathological analysis. Q-PCR analysis showed 
that Trf1 was successfully deleted from heart, intestine, lung, skin, blood, liver, kidney, bone marrow, 
brain and stomach (Figure 32a). TRF1 immunofluorescence in skin and small intestine sections 
confirmed depletion of TRF1 protein in these tissues (Figure 32b). Despite successful TRF1 depletion 
after seven weeks in a tamoxifen-containing diet, neither Trf1+/+ nor Trf1Δ/Δ showed signs of viability loss 
or decreased survival (Figure 32c). Histopathological analysis of the tissues revealed that the Trf1Δ/Δ 
hUBC-CreERT2 mice only showed minor alterations affecting only some of the mice and tissues (Figure 
32d). 
 
 
 
Figure 32. Systemic TRF1 depletion in healthy tissues does not compromise tissue function nor organism viability. (A) Trf1 
expression levels in the indicated tissues of wild type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for 
seven weeks. (B)  Representative images of TRF1 immunofluorescence and quantification of the percentage of TRF1-positive cells 
in in skin and intestine sections of wild type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen containing diet for seven 
weeks. (C) Survival curve of wild type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for seven weeks. 
(D) Quantification of the histological alterations observed in tamoxifen treated Trf1lox/lox hUBC-CreERT2 mice compared to their wild-
type counterparts.  
 
 
TRF1-depleted basal skin, intestinal crypts and bone marrow progenitors presented 
anisocytosis (Figure 33a-b, Figure 34a). Trf1-deficient basal skin displayed areas with low cellularity 
and follicular cysts (Figure 33a). Trf1Δ/Δ intestinal crypts showed an increased number of mitosis but no 
reduction in microvilli length was detected (Figure 33b-c). Trf1Δ/Δ bone marrow presented 
megakaryocytes with reduced cytoplasm (Figure 34a).  
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Figure 33. Trf1-deficient skin and intestine show minor histological alterations and no change in microvilli length. (A) 
Representative images of tamoxifen treated wild type and Trf1lox/lox hUBC-CreERT2  skin. A hair follicle cyst is indicated by an arrow. 
Anysocaryosis is indicated by black arrow heads. (B) Representative images of tamoxifen treated wild type and Trf1lox/lox hUBC-
CreERT2 intestine. Giant nuclei and mitotic figures are indicated by yellow and black arrow heads, respectively. Quantification of 
microvilli length in tamoxifen treated wild type and Trf1lox/lox hUBC-CreERT2 intestine. Error bars represent standard error. The 
number of mice analyzed per genotype is indicated in each case. T-test was used for statistical analysis.  
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Figure 34. Trf1-deficient bone marrow histological analysis. (A) Representative images of tamoxifen treated wild type and 
Trf1lox/lox hUBC-CreERT2 bone marrow. The TRF1-depleted bone marrow shows some areas of moderate aplasia and 
megakaryocytes with small cytoplasm (black arrow heads). (B) Quantification of blood cell populations in tamoxifen-treated wild type 
and Trf1lox/lox hUBC-CreERT2. 
 
 
Blood counts showed a small decrease in the number of platelets and lymphocytes (Figure 
34b). Of note, only one Trf1Δ/Δ hUBC-CreERT2 mouse showed a moderate bone marrow aplasia (Figure 
32d, Figure 34a). Importantly, tamoxifen retrieval from the diet resulted in a rapid raise of Trf1 
expression levels. Indeed, after two weeks placing the mice on standard diet, Trf1 levels in blood, 
intestine, skin and bone marrow increased 20-, 10-, 30- and 200- fold, respectively, compared to the 
levels observed in mice on tamoxifen diet (Figure 35a). After 2 weeks in a normal diet, platelets blood 
counts were also recovered to wild-type levels (Figure 35b). All together, these data underline the 
reversibility of TRF1 depletion and support that a transient ubiquitous TRF1 downregulation is 
compatible with mouse viability. 
 
 
Figure 35. TRF1 downregulation and platelets/lymphocytes reduction revert upon tamoxifen retrieval. (A) Fold increase in 
Trf1 expression levels in blood, intestine, skin and bone marrow of Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-
containing diet for seven weeks and after two weeks tamoxifen retrieval. (B) Quantification of blood cell populations in wild-type and 
Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for seven weeks and after two weeks of tamoxifen retrieval. 
Error bars represent standard error. The number of mice analyzed per genotype is indicated in each case. T-test was used. *, 
p=0.05; **, p<0.01. TMX: tamoxifen. 
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PART 1. In vivo role of CHK2 in the signalling of dysfunctional 
telomeres 
 
 
1.1. Importance of the DDR in the signalling of dysfunctional telomeres and its consequences for 
aging 
 Aging is a multifactorial process induced by alterations in different molecular systems (Finkel et 
al, 2007). The exact nature and relative contribution of each is still unknown. One possibility is that aging 
partially results from the functional decline of adult stem cells. However, the mechanisms behind this 
functional decline -how the stem cells lose their proliferative and regenerative potential- are not fully 
understood. One of the mechanisms that contributes to the aging of stem cells is the telomere 
shortening due to insufficient telomerase activity (Flores et al, 2008; Flores et al, 2005; Zimmermann & 
Martens, 2005). It has been proposed that DNA damage accumulation and a p53-dependent response 
induce stem cell senescence and loss of the proliferative potential of stem cells with short telomeres 
(Flores & Blasco, 2009). Indeed, the abrogation of p53 or p21 in telomere dysfunction mouse models 
has proven to be effective in rescueing the regenerative potential of stem cells and in the case of p21, to 
improve the organism survival (Chin et al, 1999; Choudhury et al, 2007; Flores & Blasco, 2009). 
Interestingly, not only the direct abrogation of p21 or p53 is effective to that end, but also the abrogation 
of other DDR factors that result in decreased p21/p53 activation is effective and has proven to 
ameliorate organism fitness in telomere dysfunction mouse models. Namely, the abrogation of DDR 
factors Exo1 or Pms2 in Terc-deficient mice leads to an improved stem cell condition and increased 
survival, without increasing cancer incidence (Schaetzlein et al, 2007; Siegl-Cachedenier et al, 2007; 
Sperka et al, 2012). In both Terc/Pms2 and Terc/Exo1 models, the mechanism proposed to explain the 
increased survival and fitness of the stem cells is a decrease in DNA damage load and in p21/p53 
levels. In contrast to Exo1 and Pms2-deficient models, abrogation of the DNA repair component Msh2 in 
Terc-deficient mouse model leads to an increase in stem cell proliferation, but also to increased cancer 
incidence and no survival improvement (Martinez et al, 2009a).  
Altogether, these data indicate that the condition and regenerative potential of aged stem cells 
can be improved by abrogation of specific components of the DDR, while protecting genetic stability and 
thus preventing cancer onset.  
 
 
1.2. Importance of the DDR effector CHK2 in the signalling of dysfunctional telomeres 
In this study, we aimed to address the role of CHK2 in the cellular response to dysfunctional 
telomeres. This issue had been previously addressed in several in vitro studies with human cells, with 
confusing conclusions (Cesare et al, 2013; Thanasoula et al, 2012). Cesare and coworkers claimed that 
telomere deprotection resulting from knocking down TRF2 levels without depleting completely TRF2 and 
without inducing telomere-telomere fusions results in p53-mediated cell cycle arrest in G1 independently 
of CHK2 phosphorylation (Cesare et al, 2013). However, when telomeres are fully depleted for TRF2 
they undergo chromosome fusions and induce CHK2 phosphorylation. The authors concluded that very 
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few TRF2 molecules at telomeres are sufficient to prevent the non-homologous end joining pathway 
(NHEJ) and to inhibit CHK2 activation, and thereby allowing the cells to continue through mitosis 
avoiding the G2/M arrest (Cesare et al, 2013). This stands in contrast with the results obtained by 
Thanasoula and coworkers, that claimed that telomere deprotection in human cells resulting from TRF2 
depletion leads to CHK2 phosphorylation and to a clear G2/M arrest (Thanasoula et al, 2012). This 
blocks mitotic entry in the presence of uncapped telomeres (Thanasoula et al, 2012). 
In mouse, it has been shown that dysfunctional telomeres induced by Trf1 deletion lead to 
CHK2 phosphorylation and G2/M arrest (Martinez et al, 2009b). Furthermore, abolishment of end-to-end 
fusions owing to Trf1-deficiency by simultaneously deleting 53bp1, and essential component of the 
NHEJ, does not inhibit CHK2 phosphorylation or “in vivo” G2/M arrest (Martinez et al, 2012). Similarly, 
mouse cells depleted for Trf2 and lacking ligase 4, another essential component of the NHEJ, do not 
show telomere-telomere fusions but show CHK2 phosphorylation (Celli & de Lange, 2005). Thus, in 
contrast to human cells, mouse telomere dysfunction induced by either depleting TRF1 or TRF2 leads to 
CHK2 phosphorylation independently of chromosome fusions. 
 
 
1.2.1. Chk2 deficiency improves the survival of Trf1-deficient mice and early-generation Terc-
deficient mice 
We found that Chk2 deficiency partially rescues both Terc deficiency in early generations and 
Trf1 deficiency-associated phenotypes, thus demonstrating a role for CHK2 in signalling telomere 
dysfunction in vivo. Furthermore, we demonstrate that this rescue is not mediated by a rescue of the 
amount of DNA damage but instead reflects an attenuation of the proliferative defects associated to 
p53/p21 induction. A previous work reported that Chk2 deletion in mice did not rescue survival or 
pathologies associated to Terc-deficiency (Nalapareddy et al, 2010). Although our findings may seem to 
stand in contrast to those reported by Nalapareddy (Nalapareddy et al, 2010), it is relevant to note that 
these authors only focused their study in late generation iG4 telomerase deficient mice which 
correspond to our G3 generation bearing very short telomeres and where we also do not see CHK2-
mediated rescue. In contrast to our current study, Nalapareddy et al. did not address the effect of Chk2 
deficiency in signalling critically short telomeres in G1 or G2 telomerase-deficient mice, which is where 
we observe a significant partial rescue in median survival by Chk2 deficiency. In addition, the different 
outcomes might also be due to the different ways both groups have generated the Terc-deficient mouse 
cohorts. Thus, Nalapareddy et al. crossed G3 Terc-/- Chk2+/-  with Terc+/- Chk2+/- to generate their 
experimental cohorts; namely, Terc+/- Chk2+/+ (iF1 Chk2+/+), Terc+/- Chk2-/- (iF1 Chk2-/-), Terc-/- Chk2+/+ 
(iG4 Chk2+/+) and Terc-/- Chk2-/- (iG4 Chk2+/+). The zygotes in all these cohorts harbor half of its 
chromosomes with long telomeres (those coming from the Terc+/- parental) and half with short telomeres 
(those coming from the G3 Terc-/- parental). In our work, we carried the Terc- allele in homozygosis from 
the first generation of G1 Terc-/- Chk2+/- throughout the G2 and G3 generations, thus in a setting where 
all chromosomes present progressively shortened telomeres.  
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1.2.2. CHK2-independent mechanisms might account for the partial rescue of survival in the 
Trf1∆/∆ K5-Cre and G3 Terc-/- Chk2-/- mice 
It is conceivable that the CHK2-mediated response in Trf1∆/∆ K5-Cre and G3 Terc-deficient mice 
is masked by a compensatory induction of a CHK2-independent mechanism that leads to p53/p21 
activation. In fact, Nalapareddy et al. detected significantly higher levels of phosphorylated CHK1 in iG4 
Chk2-/- as compared to iG4 Chk2+/+ (Nalapareddy et al, 2010). In agreement with Nalapareddy et al., we 
also detected a slight increase in CHK1 phosphorylation in the absence of CHK2 in Trf1-deficient 
keratinocytes, which explains the fact that p53 levels were still elevated in Chk2 cohorts compared to the 
wild-types. This fact also explains that Chk2 deficiency only partially rescued survival and phenotypes 
associated to Trf1 deficiency, while p53 deficiency was previously described by us to fully rescue Trf1∆/∆ 
K5-Cre perinatal lethality (Martinez et al, 2009b). Thus, in the absence of CHK2, other components of 
the DDR, including CHK1 may be important to signal telomere dysfunction.  
Finally, although single Chk2 deficiency has not been associated to increased cancer (Barlow et 
al, 1996; Donehower et al, 1992; Hirao et al, 2002), we found a slightly increased cancer incidence in 
the absence of Chk2 in the context of both Trf1 and Terc deficiencies. These findings are in line with 
increased cancer incidence associated to telomere dysfunction in the absence of p53 (Chin et al, 1999; 
Martinez et al, 2009b).   
 
 
 
 
 
In summary, our findings represent the first demonstration in vivo for a role of Chk2 in signalling 
telomere dysfunction owing to both short telomeres and severe telomere uncapping. 
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PART 2. Targeting TRF1 as an anti-cancer therapy in a lung 
cancer mouse model 
 
 
2.1. Targeting telomere capping for cancer therapy, a mechanism independent of telomere length  
Cancer cells present short telomeres and are dependent on the acquisition of telomere 
elongation systems to sustain their unlimited growth. It has been suggested that when the telomeres of 
cancer cells become critically short, they undergo a “telomere crisis” (Blasco, 2002; Maser & DePinho, 
2002). At that point, the acquisition of a mechanism to elongate telomeres becomes necessary for the 
tumor to progress to malignancy. Aberrant telomerase activation is a common feature of human 
cancers, where it allows the growth of malignant cells by ensuring maintenance of a minimal functional 
telomere length that permits cell division (Gonzalez-Suarez et al, 2000; Hahn et al, 1999; Kim et al, 
1994). Indeed, mutations in the telomerase gene or its regulatory regions have been found associated to 
many different types of cancer (Bojesen et al, 2013; Garcia-Closas et al, 2013; Horn et al, 2013; Huang 
et al, 2013; McKay et al, 2008; Melin et al, 2012; Mocellin et al, 2012; Petersen et al, 2010; Rafnar et al, 
2009; Shete et al, 2009; Wang et al, 2008).  
To date, targeting of telomeres in human cancer has been mainly via targeting telomerase 
activity, typically through direct small molecule inhibitors of the enzyme activity (Brennan et al, 2010; 
Joseph et al, 2010), or through immunotherapy-based approaches (Brunsvig et al, 2006; Suso et al, 
2011). Molecules that stabilize G4 quadruplexes have also been proposed as potential avenues to 
inhibit telomerase-mediated telomere elongation in cancer (Huang et al, 2008; Shin-ya et al, 2001; Sun 
et al, 1997). However, therapeutic strategies based on telomerase inhibition to treat cancer present 
shortcomings. First, telomerase inhibition in cancer therapy has been shown to lead to the acquisition of 
alternative systems of telomere elongation (Hu et al, 2012). Secondly, telomerase inhibition will be 
effective only when telomeres shorten below a minimum length. Indeed, telomerase activity is 
dispensable for transformation of cells with long telomeres (Seger et al, 2002), and studies with 
telomerase inhibitors indicate that they are effective preferentially in cells with short telomeres (Brennan 
et al, 2010; Hahn et al, 1999; Herbert et al, 1999; Wang et al, 2004; Wu et al, 2012b) reviewed in 
(Buseman et al, 2012). In the context of cancer prone mouse models, telomerase abrogation only 
showed anti-tumorigenic activity after several mouse generations in the absence of telomerase when 
telomeres reached a critically short length (Chin et al, 1999; Gonzalez-Suarez et al, 2000; Greenberg et 
al, 1999). Moreover, these anti-tumorigenic effects of short telomeres owing to telomerase deficiency 
are abrogated in the absence of p53 (Artandi et al, 2000; Chin et al, 1999). Similar results were recently 
obtained when the impact of telomerase abrogation was addressed in the context of the K-RasG12D lung 
carcinogenesis mouse model (Perera et al, 2008). In this study, short telomeres owing to five mouse 
generations in the absence of telomerase delayed but did not prevent tumor formation in a p53-proficient 
background (Perera et al, 2008). Moreover, in a p53 heterozygous background, the K-Ras+/G12D Terc-/- 
p53+/- mice developed very aggressive tumors with higher incidence of chromosomal instability and 
higher metastatic potential that lead to a significant decrease of the overall survival as compared to their 
wild-type Terc counterparts (Perera et al, 2008). This is in contrast with our findings, which showed that 
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in a p53-proficient background, Trf1 deficiency fully blocks tumor development. Furthermore, our results 
demonstrate that Trf1 depletion in a p53-deficient background still impairs tumor growth and progression 
to malignancy. Thus, our data strongly support the notion that acute telomere uncapping is a more rapid 
and efficient strategy to block lung tumorigenesis than telomerase inhibition.  
In contrast to telomerase inhibition and G4 stabilization, telomere uncapping has been shown to 
cause rapid induction of cell death and/or senescence in a manner that is independent of telomerase 
activity and telomere length (Karlseder et al, 1999; Martinez et al, 2009b; Smogorzewska & de Lange, 
2002). Targetting telomere capping for therapy approaches would imply to target a protein that has a 
structural and non-enzymatic function. This approach is already been used in cancer therapy: anti-
mitotic drugs such as Taxol (paclitaxel) are agents that selectively perturb mitosis progression, ultimately 
leading to mitotic catastrophe and cancer cell death (Janssen & Medema, 2011; Manchado et al, 2012). 
Targeting telomere capping could be effective through the same universal principle of mitotic drugs, by 
specifically impairing the growth of dividing cells. 
 
 
2.1.1. Trf1 abrogation impairs growth and progression independently of p53 genetic background 
Our results show that in a p53-proficient background Trf1-deficient tumors are not able to 
develop, suggesting that Trf1 abrogation is an important anti-cancer barrier. In this p53-proficient setting, 
the only tumors that eventually manage to grow are Trf1 wild type (“escapers”). They originate from a 
rare event: a cell that has excised the stop cassette of the K-rasG12V oncogene (activating its expression) 
but has not excised Trf1lox. The lower probability of this event explains why those unexcised 
Trf1lox/loxp53+/+ tumors have a later onset compared to the Trf1+/+ p53+/+ tumors.   
In contrast, in a p53-deficient background, Trf1 deficiency is not able to prevent tumor onset: 
Trf1∆/∆ p53-/- tumors develop. This is in agreement with previous work, in which the abrogation of p53 in 
Trf1 and Terc-deficient mouse models abolished the tumor suppressor effect of dysfunctional telomeres 
(Artandi et al, 2000; Chin et al, 1999; Martinez et al, 2009b). Moreover, Trf1 abrogation results in a 
dramatic reduction in the number and the size of malignant lung carcinoma lesions, indicating that Trf1 
deficiency severely impairs cancer progression in the context of oncogenic K-Ras, even in the absence 
of p53. As a consequence of this, all the Trf1∆/∆ K-Ras+/G12V p53-/- survived until the end-point of the 
experiment, while only 50% of the Trf1+/+ K-Ras+/G12V p53-/- mice survived the same period. Although it 
would have been interesting to further follow the progression of Trf1Δ/Δ K-Ras+/G12V p53-/- tumors for a 
longer time than 24 weeks, it was impossible owing to the fact that p53-deficient mice have a maximum 
life-span of six months due to lymphomas/sarcomas development (Donehower et al, 1992).  
In addition to the study of Trf1 deficiency impact on tumor onset, growth and progression, we 
have also addressed the effect of TRF1 downregulation in the growth and metastatic potential of 
already-established tumor cells, which is of a special interest for the therapeutic point of view. Indeed, 
we have shown that downregulation of TRF1 can also block the growth and metastatic potential of both 
mouse and human lung cancer cell lines derived from already established K-Ras induced lung 
carcinomas by using xenograph models. One of the aims of future work will be to confirm these data in 
vivo, by generating a mouse model that will allow the study of Trf1 deletion in vivo once the tumors have 
formed.  
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2.1.2. Mechanisms through which Trf1 deletion impairs lung tumorigenesis   
We found that the mechanisms through which Trf1 deletion impairs cancer progression are 
related to its previously described roles in telomere capping, telomere replication, and mitosis (Martinez 
et al, 2009b; Sfeir et al, 2009). Namely, Trf1 deletion causes replication fork stalling (Sfeir et al, 2009). In 
a context of oncogenic stress induced by K-rasG12V expression, it is likely that the replicative stress due 
to oncogenic signalling combined with the replicative defect caused by Trf1 deficiency would cause a 
synthetic lethality of cancer cells. Indeed, the combination of replicative stress and Trf1 deficiency would 
further aggravate the DNA damage generated in the cells and thus explain the increased telomeric DNA 
damage, cell cycle arrest, catastrophic mitosis and apoptosis observed in Trf1-deficient tumors.  
 
 
2.2. TRF1 ubiquitous downregulation does not compromise organism viability 
To demonstrate that TRF1 inhibition is a good strategy for cancer therapy, the first issue to be 
addressed was whether a transient TRF1 downregulation was not lethal for the organism.  
In order to assess the impact of Trf1 deletion in the adult organism, we generated a new mouse 
model, Trf1lox/lox hUBC-CreERT2 mice, which allows whole-body Trf1 deletion in adult tissues upon 
administration of a tamoxifen diet. By using this model, we have shown that mice with transient systemic 
deletion of Trf1 in most adult tissues during more than 1.5 months showed normal mouse viability 
without detectable signs of sickness or tissue dysfunction. Indeed, upon full histopathological analysis, 
we only found minor histological alterations. Furthermore, we show that 2 weeks after the removal of 
tamoxifen diet, Trf1 levels were increasing and blood cell counts were normal, suggesting a reversibility 
of TRF1 transient depletion. With the data of this model, we demonstrated here that a transient systemic 
depletion of TRF1 in healthy adult tissues is reversible and does not compromise organism viability, thus 
supporting the existance of a window of opportunity for TRF1 inhibition in cancer cells without 
significantly affecting organismal fitness.  
 
 
 
 
Together, these findings suggest that TRF1 inhibition could effectively block both tumor formation and 
malignant progression without deleterious effects on organismal viability. 
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1. Role of CHK2 in the signalling of telomere dysfunction 
 
1.1. Chk2 deficiency increases mouse survival and ameliorates the degenerative pathologies associated 
to telomere dysfunction, in Trf1-deficient mice and in G1-G2 Terc-deficient mice. 
 
1.2. Chk2 deficiency reduces p53 induction and increases proliferation in both mouse models.  
 
1.3. Chk2 deficiency attenuates the tumor suppressor effect of dysfunctional telomeres. 
 
 
 
2. TRF1 as a target for anti-cancer therapy 
 
2.1. Trf1 deficiency induces senescence, and impairs the proliferation and the immortalization of MEFs 
expressing the K-RasG12V oncogene.  
 
2.2. Trf1 deficiency inhibits K-RasG12V-mediated lung cancer development, in a p53-proficient genetic 
background. 
 
2.3. Trf1 deficiency impairs K-RasG12V-mediated lung cancer growth and progression, and increases 
mouse survival, in a p53-deficient genetic background. 
 
2.4. Lung carcinomas deficient for Trf1 show increased telomeric DNA damage, lower proliferation, G2-
arrest and mitotic defects. 
 
2.5. TRF1 downregulation in mouse and human cell lines derived from mutated K-Ras lung carcinomas 
impairs their metastatic potential and growth in allograft and xenograft experiments. 
 
2.6. Transient whole-body Trf1 deficiency is compatible with survival and normal tissue function. 
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1. Papel de CHK2 en la señalización de la disfunción telomérica 
 
1.1. La ausencia de Chk2 en los ratones deficientes para Trf1 y en las generaciones G1-G2 de ratones 
deficientes para Terc aumenta la supervivencia y mejora las patologías degenerativas asociadas a la 
disfunción telomérica.  
 
1.2. La deficiencia de Chk2 reduce la inducción de p53 e incrementa la proliferación en ambos modelos 
murinos.  
 
1.3. La deficiencia de Chk2 atenúa el efecto supresor de tumores ejercido por los telómeros 
disfuncionales.  
 
 
 
2. TRF1 como una diana para la terapia anti-cáncer 
 
2.1. La deficiencia de Trf1 induce senescencia, y dificulta la proliferación e inmortalización de MEFs que 
expresan el oncogén K-RasG12V.  
 
2.2. La deficiencia de Trf1 inhibe el desarrollo del cáncer de pulmón mediado por K-RasG12V, en un 
fondo genético competente para p53. 
 
2.3. La deficiencia de Trf1 inhibe el crecimiento y la progresión del cáncer de pulmón mediado por K-
RasG12V, y aumenta la supervivencia de los ratones, en un fondo genético deficiente en p53. 
 
2.4. Los carcinomas de pulmón deficientes en Trf1 presentan mayor cantidad de daño al ADN 
telomérico, inferior proliferación, arresto en G2 y defectos mitóticos. 
 
2.5. La disminución de los niveles de TRF1 en líneas celulares humanas y de ratón, derivadas de 
carcinomas de pulmón con K-ras mutado, osbtaculiza su crecimiento y potencial metastásico en 
experimentos de alotransplante y xenotransplante. 
 
2.6. La deficiencia transitoria y ubicua de Trf1 es compatible con la supervivencia y normal 
funcionamiento de los tejidos. 
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